Compositions and methods for enhancing protein production in fungal cells

Recombinant filamentous fungal strains deficient in specific regulatory proteins and overexpressing targeted genes improve protein production efficiency, addressing the need for enhanced industrial enzyme production.

JP2024542623APending Publication Date: 2024-11-15DANISCO US INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024531680
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-11-11
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

There is a continuous need for improved filamentous fungal strains that enhance the production of proteins of interest, such as cellulases and other enzymes, for industrial applications, as current strains do not adequately address the need for increased production efficiency and productivity.

Method used

The development of recombinant filamentous fungal strains that are deficient in the production of certain natural regulatory proteins and overexpress specific genes encoding these proteins, allowing for enhanced protein production properties, including total protein production and enzymatic activity.

Benefits of technology

The recombinant fungal strains exhibit improved protein production characteristics, such as increased total protein production and enhanced enzymatic activity, making them suitable for industrial-scale fermentation processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542623000020
    Figure 2024542623000020
  • Figure 2024542623000021
    Figure 2024542623000021
  • Figure 2024542623000022
    Figure 2024542623000022
Patent Text Reader

Abstract

The present disclosure relates generally to recombinant fungal strains for use in commercial-scale production of proteins (polypeptides) of interest. Certain embodiments relate to recombinant fungal strains of the present disclosure that are deficient in the production of one or more native (endogenous) regulatory proteins and / or overexpression of one or more regulatory proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 284,875, filed December 1, 2021, which is incorporated by reference herein in its entirety.

[0002] The present disclosure relates generally to the fields of molecular biology, biochemistry, regulatory proteins, industrial fermentation, protein production, filamentous fungi, etc. Certain embodiments of the present disclosure relate to mutant fungal cells and methods thereof for use in enhancing production of a protein of interest.

[0003] Sequence Listing The sequence listing text file submitted herewith contains the file "NB41575-WO-PCT_SequenceListing.xml", created on November 11, 2022, and is 228 kilobytes (KB) in size. This sequence listing complies with 37 C.FR § 1.52(e) and is hereby incorporated by reference in its entirety. [Background technology]

[0004] Many of the biopolymer degrading hydrolytic enzymes, such as cellulases, hemicellulases, ligninases, and pectinases, have attracted attention for their potential applications in the food, feed, fiber, pulp and paper industries, etc. For example, industrial filamentous fungal production strains, particularly Aspergillus and Trichoderma strains, can produce large amounts of these extracellular enzymes. Similarly, hypersecreting strains and the presence of strong promoters, such as cellulase (gene) promoters, make filamentous fungal cells particularly suitable for heterologous protein production.

[0005] Thus, filamentous fungi are capable of expressing native and heterologous proteins at high levels and are well suited for large-scale production of enzymes and other proteins, such as for industrial, pharmaceutical, animal health, and food and beverage applications. Despite the current knowledge in the art regarding filamentous fungal strains, there is a continuous and continuing need in the art for improved strains for use in the production of proteins of interest. As described herein, the recombinant filamentous fungal strains of the present disclosure are well suited for use in industrial-scale fermentation processes to enhance production of endogenous and / or heterologous proteins of interest. Summary of the Invention [Means for solving the problem]

[0006] As described herein, the present disclosure provides compositions and methods for constructing, obtaining, screening, identifying, inter alia, recombinant (genetically modified) filamentous fungal strains deficient in the production of a particular native regulatory protein, recombinant fungal strains overexpressing a particular gene encoding a native regulatory protein, recombinant fungal strains deficient in the production of a particular native regulatory protein and overexpressing a particular gene encoding a native regulatory protein, recombinant fungal strains producing a protein of interest, etc. Thus, certain embodiments relate to, inter alia, recombinant fungal cells (strains) deficient in the production of one or more regulatory proteins comprising at least 80% identity to a regulatory protein listed in Table 1, recombinant fungal cells overexpressing one or more regulatory proteins comprising at least 80% identity to a regulatory protein listed in Table 10, recombinant fungal cells deficient in the production of one or more regulatory proteins listed in Table 1 and overexpressing one or more regulatory proteins listed in Table 10, etc.

[0007] In other aspects, the recombinant fungal cells express a protein of interest. In certain embodiments, the protein of interest includes, but is not limited to, an enzyme, a peptide, an antibody and / or a functional antibody fragment thereof, a receptor protein, an animal feed protein, a human food protein, a protein biologic, a therapeutic protein, an immunogenic protein, and the like. Accordingly, certain other aspects of the present disclosure relate to methods of constructing, obtaining, screening, identifying recombinant fungal strains that include, among others, enhanced protein production characteristics / phenotypes, such as total protein production, enzyme activity, cellulose (PASC) hydrolysis, protein production rate, and the like. [Brief description of the drawings]

[0008] [Figure 1A-1H]Figure 1 shows the amino acid sequences of regulatory proteins identified in certain Trichoderma species, filamentous fungal regulatory protein deletion libraries described in the Examples section below. More specifically, as shown in Figure 1A, regulatory protein "Trire2_4933" comprises the predicted full-length amino acid sequence of SEQ ID NO:2 and the predicted DNA binding domain (hereinafter "DBD") subsequence therein, as shown in SEQ ID NO:3; regulatory protein "Trire2_5675" comprises the predicted full-length amino acid sequence of SEQ ID NO:5 and the predicted DBD subsequence therein, as shown in SEQ ID NO:6; regulatory protein "Trire2_48438" comprises the predicted full-length amino acid sequence of SEQ ID NO:8 and the predicted DBD subsequence therein, as shown in SEQ ID NO:9; and regulatory protein "Trire2_49232" comprises the predicted full-length amino acid sequence of SEQ ID NO:11 and the predicted DBD subsequence therein, as shown in SEQ ID NO:12. As shown in FIG. 1B, the regulatory protein "Trire2_55105" comprises the predicted full-length amino acid sequence of SEQ ID NO:14 and the predicted DBD subsequence therein, as shown in SEQ ID NO:15; the regulatory protein "Trire2_60565" comprises the predicted full-length amino acid sequence of SEQ ID NO:17 and the predicted DBD subsequence therein, as shown in SEQ ID NO:18; and the regulatory protein "Trire2_60931" comprises the predicted full-length amino acid sequence of SEQ ID NO:20 and the predicted DBD subsequence therein, as shown in SEQ ID NO:21. As shown in FIG. 1C, the regulatory protein "Trire2_67209" comprises the predicted full-length amino acid sequence of SEQ ID NO:23 and the predicted DBD subsequence therein, as shown in SEQ ID NO:24; the regulatory protein "Trire2_68097" comprises the predicted full-length amino acid sequence of SEQ ID NO:26 and the predicted DBD subsequence therein, as shown in SEQ ID NO:27; and the regulatory protein "Trire2_68425" comprises the predicted full-length amino acid sequence of SEQ ID NO:29 and the predicted DBD subsequence therein, as shown in SEQ ID NO:30.As shown in FIG. 1D, the regulatory protein "Trire2_69695" comprises the predicted full-length amino acid sequence of SEQ ID NO:32 and the predicted DBD subsequence therein, as shown in SEQ ID NO:33; the regulatory protein "Trire2_71823" comprises the predicted full-length amino acid sequence of SEQ ID NO:35 and the predicted DBD subsequence therein, as shown in SEQ ID NO:36; and the regulatory protein "Trire2_72993" comprises the predicted full-length amino acid sequence of SEQ ID NO:38 and the predicted DBD subsequence therein, as shown in SEQ ID NO:39. As shown in FIG. 1E, the regulatory protein "Trire2_76705" comprises the predicted full-length amino acid sequence of SEQ ID NO:41 and the predicted DBD subsequence therein, as shown in SEQ ID NO:42; the regulatory protein "Trire2_76872" comprises the predicted full-length amino acid sequence of SEQ ID NO:44 and the predicted DBD subsequence therein, as shown in SEQ ID NO:45; and the regulatory protein "Trire2_77291" comprises the predicted full-length amino acid sequence of SEQ ID NO:47 and the predicted DBD subsequence therein, as shown in SEQ ID NO:48; and the regulatory protein "Trire2_78162" comprises the predicted full-length amino acid sequence of SEQ ID NO:50 and the predicted DBD subsequence therein, as shown in SEQ ID NO:51. As shown in FIG. 1F, the regulatory protein "Trire2_103122" comprises the predicted full-length amino acid sequence of SEQ ID NO:53 and the predicted DBD subsequence therein, as shown in SEQ ID NO:54; the regulatory protein "Trire2_105239" comprises the predicted full-length amino acid sequence of SEQ ID NO:56 and the predicted DBD subsequence therein, as shown in SEQ ID NO:57; and the regulatory protein "Trire2_105849" comprises the predicted full-length amino acid sequence of SEQ ID NO:59 and the predicted DBD subsequence therein, as shown in SEQ ID NO:60; and the regulatory protein "Trire2_108013" comprises the predicted full-length amino acid sequence of SEQ ID NO:62 and the predicted DBD subsequence therein, as shown in SEQ ID NO:63.As shown in FIG. 1G, the regulatory protein "Trire2_108775" comprises the predicted full-length amino acid sequence of SEQ ID NO:65 and the predicted DBD subsequence therein, as shown in SEQ ID NO:66; the regulatory protein "Trire2_119986" comprises the predicted full-length amino acid sequence of SEQ ID NO:68 and the predicted DBD subsequence therein, as shown in SEQ ID NO:69; and the regulatory protein "Trire2_120428" comprises the predicted full-length amino acid sequence of SEQ ID NO:71 and the predicted DBD subsequence therein, as shown in SEQ ID NO:72. As shown in FIG. 1H, the regulatory protein "Trire2_120597" comprises the predicted full-length amino acid sequence of SEQ ID NO:74 and the predicted DBD subsequence therein, as shown in SEQ ID NO:75; the regulatory protein "Trire2_121757" comprises the predicted full-length amino acid sequence of SEQ ID NO:77 and the predicted DBD subsequence therein, as shown in SEQ ID NO:78; and the regulatory protein "Trire2_122783" comprises the predicted full-length amino acid sequence of SEQ ID NO:81 and the predicted DBD subsequence therein, as shown in SEQ ID NO:80. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] A brief description of biological sequences SEQ ID NO:1 is a Trichoderma reesei nucleic acid (DNA) sequence encoding a regulatory protein designated "Trire2_4933 (PID 4933)."

[0010] SEQ ID NO:2 is the predicted amino acid sequence of the Trire2_4933 (PID 4933) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:1.

[0011] SEQ ID NO: 3 is the amino acid sequence of a putative DNA binding domain (hereinafter referred to as "DBD") present in the Trire2_4933 (PID 4933) regulatory protein of SEQ ID NO: 2.

[0012] SEQ ID NO:4 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_5675 (PID 5675)."

[0013] SEQ ID NO:5 is the predicted amino acid sequence of the Trire2_5675 (PID 5675) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:4.

[0014] SEQ ID NO:6 is the amino acid sequence of the predicted DBD representing the Trire2_5675 (PID 5675) regulatory protein of SEQ ID NO:5.

[0015] SEQ ID NO:7 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_48438 (PID 48438)."

[0016] SEQ ID NO:8 is the predicted amino acid sequence of the Trire2_48438 (PID 48438) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:7.

[0017] SEQ ID NO:9 is the amino acid sequence of the predicted DBD representing the Trire2_48438 (PID 48438) regulatory protein of SEQ ID NO:8.

[0018] SEQ ID NO:10 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_49232 (PID 49232)."

[0019] SEQ ID NO:11 is the predicted amino acid sequence of the Trire2_49232 (PID 49232) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:10.

[0020] SEQ ID NO:12 is the amino acid sequence of the predicted DBD representing the Trire2_49232 (PID 49232) regulatory protein of SEQ ID NO:11.

[0021] SEQ ID NO:13 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_55105 (PID 55105)."

[0022] SEQ ID NO:14 is the predicted amino acid sequence of the Trire2_55105 (PID 55105) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:13.

[0023] SEQ ID NO: 15 is the amino acid sequence of the predicted DBD representing the Trire2_55105 (PID 55105) regulatory protein of SEQ ID NO:14.

[0024] SEQ ID NO: 16 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_60565 (PID 60565)."

[0025] SEQ ID NO:17 is the predicted amino acid sequence of the Trire2_60565 (PID 60565) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:16.

[0026] SEQ ID NO: 18 is the amino acid sequence of the predicted DBD representing the Trire2_60565 (PID 60565) regulatory protein of SEQ ID NO: 17.

[0027] SEQ ID NO:19 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_60931 (PID 60931)".

[0028] SEQ ID NO:20 is the predicted amino acid sequence of the Trire2_60931 (PID 60931) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:19.

[0029] SEQ ID NO:21 is the amino acid sequence of the predicted DBD representing the Trire2_60931 (PID 60931) regulatory protein of SEQ ID NO:20.

[0030] SEQ ID NO:22 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_67209 (PID 67209)."

[0031] SEQ ID NO:23 is the predicted amino acid sequence of the Trire2_67209 (PID 67209) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:22.

[0032] SEQ ID NO:24 is the amino acid sequence of the predicted DBD representing the Trire2_67209 (PID 67209) regulatory protein of SEQ ID NO:23.

[0033] SEQ ID NO:25 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_68097 (PID 68097)".

[0034] SEQ ID NO:26 is the predicted amino acid sequence of the Trire2_68097 (PID 68097) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:25.

[0035] SEQ ID NO:27 is the amino acid sequence of the predicted DBD representing the Trire2_68097 (PID 68097) regulatory protein of SEQ ID NO:26.

[0036] SEQ ID NO:28 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_68425 (PID 68425)".

[0037] SEQ ID NO:29 is the predicted amino acid sequence of the Trire2_68425 (PID 68425) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:28.

[0038] SEQ ID NO:30 is the amino acid sequence of the predicted DBD representing the Trire2_68425 (PID 68425) regulatory protein of SEQ ID NO:29.

[0039] SEQ ID NO:31 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_69695 (PID 69695)."

[0040] SEQ ID NO:32 is the predicted amino acid sequence of the Trire2_69695 (PID 69695) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:31.

[0041] SEQ ID NO: 33 is the amino acid sequence of the predicted DBD representing the Trire2_69695 (PID 69695) regulatory protein of SEQ ID NO: 32.

[0042] SEQ ID NO:34 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_71823 (PID 71823)".

[0043] SEQ ID NO:35 is the predicted amino acid sequence of the Trire2_71823 (PID 71823) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:34.

[0044] SEQ ID NO: 36 is the amino acid sequence of the predicted DBD representing the Trire2_71823 (PID 71823) regulatory protein of SEQ ID NO: 35.

[0045] SEQ ID NO:37 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_72993 (PID 72993)".

[0046] SEQ ID NO:38 is the predicted amino acid sequence of the Trire2_72993 (PID 72993) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:37.

[0047] SEQ ID NO: 39 is the amino acid sequence of the predicted DBD representing the Trire2_72993 (PID 72993) regulatory protein of SEQ ID NO: 38.

[0048] SEQ ID NO:40 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_76705 (PID 76705)".

[0049] SEQ ID NO:41 is the predicted amino acid sequence of the Trire2_76705 (PID 76705) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:40.

[0050] SEQ ID NO: 42 is the amino acid sequence of the predicted DBD representing the Trire2_76705 (PID 76705) regulatory protein of SEQ ID NO: 41.

[0051] SEQ ID NO: 43 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_76872 (PID 76872)".

[0052] SEQ ID NO:44 is the predicted amino acid sequence of the Trire2_76872 (PID 76872) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:43.

[0053] SEQ ID NO: 45 is the amino acid sequence of the predicted DBD representing the Trire2_76872 (PID 76872) regulatory protein of SEQ ID NO: 44.

[0054] SEQ ID NO: 46 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_77291 (PID 77291)".

[0055] SEQ ID NO:47 is the predicted amino acid sequence of the Trire2_77291 (PID 77291) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:46.

[0056] SEQ ID NO: 48 is the amino acid sequence of the predicted DBD representing the Trire2_77291 (PID 77291) regulatory protein of SEQ ID NO: 47.

[0057] SEQ ID NO: 49 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_78162 (PID 78162)".

[0058] SEQ ID NO:50 is the predicted amino acid sequence of the Trire2_78162 (PID 78162) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:49.

[0059] SEQ ID NO:51 is the amino acid sequence of the predicted DBD representing the Trire2_78162 (PID 78162) regulatory protein of SEQ ID NO:50.

[0060] SEQ ID NO:52 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_103122 (PID 103122)".

[0061] SEQ ID NO:53 is the predicted amino acid sequence of the Trire2_103122 (PID 103122) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:52.

[0062] SEQ ID NO: 54 is the amino acid sequence of the predicted DBD representing the Trire2_103122 (PID 103122) regulatory protein of SEQ ID NO: 53.

[0063] SEQ ID NO:55 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_105239 (PID 105239)".

[0064] SEQ ID NO:56 is the predicted amino acid sequence of the Trire2_105239 (PID 105239) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:55.

[0065] SEQ ID NO:57 is the amino acid sequence of the predicted DBD representing the Trire2_105239 (PID 105239) regulatory protein of SEQ ID NO:56.

[0066] SEQ ID NO:58 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_105849 (PID 105849)".

[0067] SEQ ID NO:59 is the predicted amino acid sequence of the Trire2_105849 (PID 105849) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:58.

[0068] SEQ ID NO: 60 is the amino acid sequence of the predicted DBD representing the Trire2_105849 (PID 105849) regulatory protein of SEQ ID NO:59.

[0069] SEQ ID NO:61 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_108013 (PID 108013)".

[0070] SEQ ID NO:62 is the predicted amino acid sequence of the Trire2_108013 (PID 108013) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:61.

[0071] SEQ ID NO: 63 is the amino acid sequence of the predicted DBD representing the Trire2_108013 (PID 108013) regulatory protein of SEQ ID NO: 62.

[0072] SEQ ID NO:64 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_108775 (PID 108775)".

[0073] SEQ ID NO:65 is the predicted amino acid sequence of the Trire2_108775 (PID 108775) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:64.

[0074] SEQ ID NO: 66 is the amino acid sequence of the predicted DBD representing the Trire2_108775 (PID 108775) regulatory protein of SEQ ID NO: 65.

[0075] SEQ ID NO:67 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_119986 (PID 119986)".

[0076] SEQ ID NO:68 is the predicted amino acid sequence of the Trire2_119986 (PID 119986) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:67.

[0077] SEQ ID NO: 69 is the amino acid sequence of the predicted DBD representing the Trire2_119986 (PID 119986) regulatory protein of SEQ ID NO: 68.

[0078] SEQ ID NO: 70 is a T. reesei nucleic acid sequence encoding a regulatory protein designated "Trire2_120428 (PID 120428)".

[0079] SEQ ID NO:71 is the predicted amino acid sequence of the Trire2_120428 (PID 120428) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:70.

[0080] SEQ ID NO: 72 is the amino acid sequence of the predicted DBD representing the Trire2_120428 (PID 120428) regulatory protein of SEQ ID NO: 71.

[0081] SEQ ID NO: 73 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_120597 (PID 120597)".

[0082] SEQ ID NO:74 is the predicted amino acid sequence of the Trire2_120597 (PID 120597) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:73.

[0083] SEQ ID NO: 75 is the amino acid sequence of the predicted DBD representing the Trire2_120597 (PID 120597) regulatory protein of SEQ ID NO: 74.

[0084] SEQ ID NO: 76 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_121757 (PID 121757)".

[0085] SEQ ID NO:77 is the predicted amino acid sequence of the Trire2_121757 (PID 121757) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:79.

[0086] SEQ ID NO: 78 is the amino acid sequence of the predicted DBD representing the Trire2_121757 (PID 121757) regulatory protein of SEQ ID NO: 80.

[0087] SEQ ID NO: 79 is a T. reesei nucleic acid sequence encoding a regulatory protein named "Trire2_122783 (PID 122783)".

[0088] SEQ ID NO: 80 is the predicted amino acid sequence of the Trire2_122783 (PID 122783) regulatory protein encoded by the nucleic acid sequence of SEQ ID NO:79.

[0089] SEQ ID NO: 81 is the amino acid sequence of the predicted DBD representing the Trire2_122783 (PID 122783) regulatory protein of SEQ ID NO: 80.

[0090] SEQ ID NO: 82 is the predicted amino acid sequence of a regulatory protein named "Trire2_1941 (PID 1941)".

[0091] SEQ ID NO: 83 is the predicted amino acid sequence of a regulatory protein named "Trire2_2148 (PID 2148)".

[0092] SEQ ID NO: 84 is the predicted amino acid sequence of a regulatory protein named "Trire2_3605 (PID 3605)".

[0093] SEQ ID NO: 85 is the predicted amino acid sequence of a regulatory protein named "Trire2_4748 (PID 4748)".

[0094] SEQ ID NO: 86 is the predicted amino acid sequence of a regulatory protein named "Trire2_5664 (PID 5664)".

[0095] SEQ ID NO: 87 is the predicted amino acid sequence of a regulatory protein named "Trire2_5927 (PID 5927)".

[0096] SEQ ID NO: 88 is the predicted amino acid sequence of a regulatory protein named "Trire2_21997 (PID 21997)".

[0097] SEQ ID NO: 89 is the predicted amino acid sequence of a regulatory protein named "Trire2_22774 (PID 22774)".

[0098] SEQ ID NO: 90 is the predicted amino acid sequence of a regulatory protein named "Trire2_22785 (PID 22785)".

[0099] SEQ ID NO: 91 is the predicted amino acid sequence of a regulatory protein named "Trire2_36703 (PID 36703)".

[0100] SEQ ID NO: 92 is the predicted amino acid sequence of a regulatory protein named "Trire2_44290 (PID 44290)".

[0101] SEQ ID NO: 93 is the predicted amino acid sequence of a regulatory protein named "Trire2_44781 (PID 44781)".

[0102] SEQ ID NO: 94 is the predicted amino acid sequence of a regulatory protein named "Trire2_45866 (PID 45866)".

[0103] SEQ ID NO: 95 is the predicted amino acid sequence of a regulatory protein named "Trire2_48773 (PID 48773)".

[0104] SEQ ID NO: 96 is the predicted amino acid sequence of a regulatory protein named "Trire2_49918 (PID 49918)".

[0105] SEQ ID NO: 97 is the predicted amino acid sequence of a regulatory protein named "Trire2_52438 (PID 52438)".

[0106] SEQ ID NO: 98 is the predicted amino acid sequence of a regulatory protein named "Trire2_52924 (PID 52924)".

[0107] SEQ ID NO: 99 is the predicted amino acid sequence of a regulatory protein named "Trire2_53106 (PID 53106)".

[0108] SEQ ID NO: 100 is the predicted amino acid sequence of a regulatory protein named "Trire2_53484 (PID 53484)".

[0109] SEQ ID NO: 101 is the predicted amino acid sequence of a regulatory protein named "Trire2_55274 (PID 55274)".

[0110] SEQ ID NO: 102 is the predicted amino acid sequence of a regulatory protein named "Trire2_56214 (PID 56214)".

[0111] SEQ ID NO: 103 is the predicted amino acid sequence of a regulatory protein named "Trire2_58130 (PID 58130)".

[0112] SEQ ID NO: 104 is the predicted amino acid sequence of a regulatory protein named "Trire2_59353 (PID 59353)".

[0113] SEQ ID NO: 105 is the predicted amino acid sequence of a regulatory protein named "Trire2_59609 (PID 59609)".

[0114] SEQ ID NO: 106 is the predicted amino acid sequence of a regulatory protein named "Trire2_60558 (PID 60558)".

[0115] SEQ ID NO: 107 is the predicted amino acid sequence of a regulatory protein named "Trire2_61476 (PID 61476)".

[0116] SEQ ID NO: 108 is the predicted amino acid sequence of a regulatory protein named "Trire2_65070 (PID 65070)".

[0117] SEQ ID NO: 109 is the predicted amino acid sequence of a regulatory protein named "Trire2_65895 (PID 65895)".

[0118] SEQ ID NO: 110 is the predicted amino acid sequence of a regulatory protein named "Trire2_68028 (PID 68028)".

[0119] SEQ ID NO: 111 is the predicted amino acid sequence of a regulatory protein named "Trire2_70414 (PID 70414)".

[0120] SEQ ID NO: 112 is the predicted amino acid sequence of a regulatory protein named "Trire2_70991 (PID 70991)".

[0121] SEQ ID NO: 113 is the predicted amino acid sequence of a regulatory protein named "Trire2_71080 (PID 71080)".

[0122] SEQ ID NO: 114 is the predicted amino acid sequence of a regulatory protein named "Trire2_71689 (PID 71689)".

[0123] SEQ ID NO: 115 is the predicted amino acid sequence of a regulatory protein named "Trire2_72076 (PID 72076)".

[0124] SEQ ID NO: 116 is the predicted amino acid sequence of a regulatory protein named "Trire2_73417 (PID 73417)".

[0125] SEQ ID NO: 117 is the predicted amino acid sequence of a regulatory protein named "Trire2_73559 (PID 73559)".

[0126] SEQ ID NO: 118 is the predicted amino acid sequence of a regulatory protein named "Trire2_73689 (PID 73689)".

[0127] SEQ ID NO: 119 is the predicted amino acid sequence of a regulatory protein named "Trire2_76039 (PID 76039)".

[0128] SEQ ID NO: 120 is the predicted amino acid sequence of a regulatory protein named "Trire2_76590 (PID 76590)".

[0129] SEQ ID NO: 121 is the predicted amino acid sequence of a regulatory protein named "Trire2_77878 (PID 77878)".

[0130] SEQ ID NO: 122 is the predicted amino acid sequence of a regulatory protein named "Trire2_1057844 (PID 105784)".

[0131] SEQ ID NO: 123 is the predicted amino acid sequence of a regulatory protein named "Trire2_105880 (PID 105880)".

[0132] SEQ ID NO: 124 is the predicted amino acid sequence of a regulatory protein named "Trire2_105917 (PID 105917)".

[0133] SEQ ID NO: 125 is the predicted amino acid sequence of a regulatory protein named "Trire2_105980 (PID 105980)".

[0134] SEQ ID NO: 126 is the predicted amino acid sequence of a regulatory protein named "Trire2_105989 (PID 105989)".

[0135] SEQ ID NO: 127 is the predicted amino acid sequence of a regulatory protein named "Trire2_106009 (PID 106009)".

[0136] SEQ ID NO: 128 is the predicted amino acid sequence of a regulatory protein named "Trire2_106720 (PID 106720)".

[0137] SEQ ID NO: 129 is the predicted amino acid sequence of a regulatory protein named "Trire2_109277 (PID 109277)".

[0138] SEQ ID NO: 130 is the predicted amino acid sequence of a regulatory protein named "Trire2_110901 (PID 110901)".

[0139] SEQ ID NO: 131 is the predicted amino acid sequence of a regulatory protein named "Trire2_119826 (PID 119826)".

[0140] SEQ ID NO: 132 is the predicted amino acid sequence of a regulatory protein named "Trire2_121164 (PID 121164)".

[0141] SEQ ID NO: 133 is the predicted amino acid sequence of a regulatory protein named "Trire2_121310 (PID 121310)".

[0142] SEQ ID NO: 134 is the predicted amino acid sequence of a regulatory protein named "Trire2_121602 (PID 121602)".

[0143] SEQ ID NO: 135 is the predicted amino acid sequence of a regulatory protein named "Trire2_122457 (PID 122457)".

[0144] SEQ ID NO: 136 is the predicted amino acid sequence of a regulatory protein named "Trire2_123713 (PID 123713)".

[0145] I. Overview As described herein, certain embodiments of the present disclosure relate to mutant (recombinant) fungal cells (strains) for use in commercial-scale production of a protein of interest. Accordingly, certain aspects relate to compositions and methods for constructing and obtaining recombinant fungal strains expressing a protein of interest. In certain aspects, as described herein, the present disclosure provides compositions and methods for constructing, obtaining, screening, identifying, among other things, recombinant (genetically modified) filamentous fungal strains defective in the production of a particular native regulatory protein, recombinant fungal strains overexpressing a particular gene encoding a native regulatory protein, recombinant fungal strains defective in the production of a particular native regulatory protein and overexpressing a particular gene encoding a native regulatory protein, recombinant fungal strains producing a protein of interest, and the like.

[0146] II. Definition Before describing the present strains, compositions and methods in further detail, the following terms and phrases are defined. Terms not defined should be accorded the ordinary meaning used and known to those of skill in the art.

[0147] All publications and patents cited herein are hereby incorporated by reference.

[0148] Where a range of values ​​is given, unless the context clearly dictates otherwise, it is understood that each intervening value, to the tenth of the unit of the lower limit between the upper and lower limits of that range, and any other stated or intervening value within that range, is encompassed within the scope of the compositions and methods. The upper and lower limits of these smaller ranges are independently included in the smaller ranges and are also encompassed within the compositions and methods of the invention, subject to any specifically excluded limit in the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the compositions and methods of the invention.

[0149] In this specification, some ranges are given by numerical values ​​preceded by the term "about." In this specification, the term "about" is used to provide literal support for the exact number it precedes, as well as a number that is close to or approximately the number it precedes. In determining whether a number is close to or approximately a specifically recited number, the unrecited near or approximate number may be a number that, in the context in which it is presented, provides a substantially equivalent number to the specifically recited number. For example, the term "about" in connection with a numerical value means the approximate value of that numerical value unless the term is specifically defined otherwise in the context. - 10%~ + 10% range. As another example, the phrase "a pH value of about 6" means a pH value of 5.4 to 6.6, unless the pH value is specifically defined otherwise.

[0150] In accordance with this detailed description, the following abbreviations and definitions apply. It should be noted that the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an enzyme" includes a plurality of such enzymes, reference to "the dosage" includes one or more dosages and equivalents thereof known to those skilled in the art, and so forth.

[0151] It is further noted that the claims may be written to exclude optional elements. Thus, this statement is intended to serve as a prelude to the use of exclusive language, such as "solely," "only," "excluding," "not including," or the use of a "negative" limitation or qualification in connection with the recitation of claim elements. For example, in certain embodiments, the qualification "the medium does not contain an inducing substrate" may be used to exclude inducing substrates such as cellulose, lactose, gentibiose, sophorose, etc.

[0152] Additionally, it should be noted that the term "comprising," as used herein, means "including, but not limited to" the component following the term "comprising." The component following the term "comprising" is required or essential, but a composition that includes this component may further include other non-essential or optional components.

[0153] It should be noted that the term "consisting of," as used herein, means "including and limited to" the component following the term "consisting of." Thus, the component following the term "consisting of" is required or essential, and other components are not present in the composition.

[0154] As will be apparent to one of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated or combined with the features of any of the other embodiments without departing from the scope or spirit of the compositions and methods described herein. Any described method may be carried out in the order of events recited or in any other order which is logically possible.

[0155] As used herein, the term "ascomycota fungal cell" refers to any organism of the Ascomycota phylum in the fungal kingdom. Examples of ascomycota fungal cells include, but are not limited to, filamentous fungi within the subphylum Pezizomycotina, such as Trichoderma species, Aspergillus species, Myceliophthora species, and Penicillium species.

[0156] As used herein, "filamentous fungi" refers to all filamentous fungal forms of the subdivision Eumycota and Oomycota. For example, filamentous fungi include, but are not limited to, species of Acremonium, Aspergillus, Emericella, Fusarium, Humicola, Mucor, Myceliophthora, Neurospora, Penicillium, Scytalidium, Thielavia, Tolypocladium, and Trichoderma.

[0157] In certain embodiments, filamentous fungi include Trichoderma species (strains), including, but not limited to, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei, and Trichoderma viride. As known to those skilled in the art, Trichoderma reesei was previously classified as "Hypocrea jecorina."

[0158] In other embodiments, the filamentous fungus is an Aspergillus sp. cell (strain), such as Aspergillus aculeatus, Aspergillus awamori, Aspergillus clavatus, Aspergillus flavus, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, or Aspergillus terreus.

[0159] As used herein, the terms "wild-type" and "native" are used interchangeably and refer to a gene, protein, fungal cell or strain as found in nature.

[0160] As used herein, the term "recombinant" or "non-naturally occurring" refers to an organism, microorganism, cell, nucleic acid molecule, or vector that has at least one genetic modification or has been modified by the introduction of a heterologous nucleic acid molecule, or to a cell (e.g., a microbial cell) that has been modified so that it can control the expression of a heterologous or endogenous nucleic acid molecule or gene. Recombinant also refers to a cell that is derived from a non-naturally occurring cell or is the descendant of a non-naturally occurring cell that has one or more such modifications. Genetic modifications include, for example, modifications that introduce an expressible nucleic acid molecule that encodes a protein, or the addition, deletion, substitution, or other functional change of other nucleic acid molecules in the genetic material of the cell. For example, recombinant cells may express genes or other nucleic acid molecules that are not found in the same or homologous form in a native (wild-type) cell, or may provide an altered expression pattern of an endogenous gene, such as being overexpressed, underexpressed, minimally expressed, or not expressed at all.

[0161] "Recombination," "recombining," or producing a "recombinant" nucleic acid generally refers to the assembly of two or more nucleic acid fragments, which assembly gives rise to a chimeric gene or polynucleotide.

[0162] As used herein, the term "gene" is synonymous with the term "allele," which refers to a nucleic acid that codes for and directs the expression of a protein or RNA. Vegetative forms of filamentous fungi are generally haploid, so a single copy of a particular gene (i.e., a single allele) is sufficient to confer a particular phenotype.

[0163] As used herein, the term "gene" refers to a segment of DNA involved in producing a polypeptide (protein) chain, and may or may not include regions preceding and following the coding region (e.g., 5' untranslated (5'UTR) or "leader" sequence, 3'UTR or "trailer" sequence, promoter sequence, terminator sequence, etc.) as well as intervening sequences (introns) between individual coding segments (exons). For example, a gene (DNA) sequence of interest (GOI) may code for a regulatory protein, a structural protein, a commercially important industrial protein or peptide, such as an enzyme (e.g., protease, mannanase, xylanase, amylase, glucoamylase, cellulase, oxidase, phytase, lipase), etc. A gene of interest may be a naturally occurring gene, a mutated (modified) gene, or a synthetic gene.

[0164] As used herein, the term "promoter" refers to a nucleic acid sequence that functions to direct transcription of a downstream gene coding sequence (CDS; or open reading frame (ORF)). A promoter is generally appropriate for the host cell (e.g., fungal cell) in which the target gene is expressed. A promoter, together with other transcriptional and translational regulatory nucleic acid sequences (also called "control sequences"), is necessary to express a given gene. In general, transcriptional and translational regulatory sequences include, but are not limited to, promoter and terminator sequences, including core promoters and enhancer or activator or repressor sequences, transcriptional and translational start and stop sequences. In certain embodiments, the promoter is an inducible promoter, a constitutive promoter, a regulatable promoter, a synthetic promoter, a tandem promoter, and combinations thereof. In certain embodiments, the inducible promoter is an inducible cellulase gene promoter.

[0165] As used herein, the term "promoter activity" is the ability of a nucleic acid to direct transcription of a downstream (3') polynucleotide in a host cell. To test promoter activity, a (promoter) nucleic acid can be operably linked to a downstream polynucleotide to produce a recombinant nucleic acid. The recombinant nucleic acid can be introduced into a cell and transcription of the polynucleotide can be evaluated. In certain cases, the polynucleotide can encode a protein and transcription of the polynucleotide can be evaluated by assessing the production of the protein in the cell.

[0166] As used herein, the term "operably linked" refers to a functional linkage between two or more nucleic acid sequences. Thus, a nucleic acid sequence is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter sequence or terminator sequence is operably linked to a gene coding sequence (CDS) if it affects the transcription of the CDS. A ribosome binding site is operably linked to a coding sequence if it is positioned to facilitate translation. A nucleic acid sequence encoding a secretory leader (i.e., signal peptide) is operably linked to a nucleic acid sequence encoding a polypeptide (e.g., ORF) if it is expressed as a preprotein that participates in the secretion of the polypeptide. In general, "operably linked" means that the DNA (nucleic acid) sequences being linked are contiguous, and in the case of a secretory leader, contiguous and in reading phase. However, enhancers need not be contiguous. Linking two or more nucleic acid sequences (i.e., operably linked) can be accomplished using any of the methods known to those skilled in the art.

[0167] As used herein, exemplary parent Trichoderma reesei strains include, but are not limited to, T. reesei strain QM6a (ATCC® 13631), T. reesei strain RL-P37 (NRRL Accession No. 15709), and T. reesei strain RUT-C30 (ATCC® 56765). Exemplary parent Aspergillus niger strains include, but are not limited to, A. niger strain ATCC® 1015. Exemplary parent Aspergillus oryzae strains include, but are not limited to, A. oryzae strain RIB40 (ATCC® 42149). And exemplary parent Myceliophthora thermophila strains include, but are not limited to, M. thermophila strain ATCC® 42464.

[0168] For example, Trichoderma strains Rut-C30 and RL-P37 are mutagenized derivatives of Trichoderma natural isolate QM6a (Le Crom et al., 2009; Sheir-Neiss and Montenecourt, 1984), with strain NG14 being the last common ancestor. In certain aspects of the present disclosure, an exemplary filamentous fungal strain is derived / obtained from T. reesei strain RL-P37 and contains a deletion of the T. reesei pyr2 gene (hereinafter abbreviated as "Δpyr2") as generally described by Sheir-Neiss and Montenecourt (1984) and WO 2011 / 153449.

[0169] As used herein, the terms "lignocellulolytic enzymes," "cellulase enzymes," and "cellulases" are used interchangeably and include glycoside hydrolase (GH) enzymes, such as cellobiohydrolases, xylanases, endoglucanases, and β-glucosidases, which hydrolyze the glycosidic bonds of cellulose (hemicellulose) to produce sugars (e.g., glucose, xylose, arabinose, etc.).

[0170] As used herein, "endoglucanase" proteins may be abbreviated as "EG", "cellobiohydrolase" proteins may be abbreviated as "CBH", "β-glucosidase" proteins may be abbreviated as "BG", and "xylanase" proteins may be abbreviated as "XYL". Thus, as used herein, genes (or ORFs) encoding EG proteins may be abbreviated as "eg", genes (or ORFs) encoding CBH proteins may be abbreviated as "cbh", genes (or ORFs) encoding BG proteins may be abbreviated as "bg", and genes (or ORFs) encoding XYL proteins may be abbreviated as "xyl". In certain embodiments, cellobiohydrolases include enzymes classified under the Enzyme Commission Number (EC 3.2.1.91), endoglucanases include enzymes classified under EC 3.2.1.4, endo-β-1,4-xylanases include enzymes classified under EC 3.2.1.8, β-xylosidases include enzymes classified under EC 3.2.1.37, and β-glucosidases include enzymes classified under EC 3.2.1.21.

[0171] As used herein, "cellulase gene promoter" includes, but is not limited to, cellobiohydrolase (cbh) gene promoter sequences, endoglucanase (for example) gene promoter sequences, β-glucosidase (bg) gene promoter sequences, xylanase (xyl) gene promoter sequences, and the like.

[0172] As used herein, the terms "modification" and "genetic modification" are used interchangeably and include: (a) the introduction, substitution or removal of one or more nucleotides in a gene, or the introduction, substitution or removal of one or more nucleotides in a regulatory element required for the transcription or translation of a gene, (b) gene disruption, (c) gene conversion, (d) gene deletion, (e) gene down-regulation and / or up-regulation, (f) specific mutagenesis and / or (g) random mutagenesis of any one or more genes / DNA sequences disclosed herein.

[0173] As used herein, the phrases "modified filamentous fungal cell," "mutated filamentous fungal cell," "recombinant fungal cell," "modified filamentous fungal strain," and the like may be used interchangeably and refer to filamentous fungal cells that are derived (i.e., derived) from a parent filamentous fungal cell belonging to the Pezizomycotina subphylum. For example, a "modified" filamentous fungal cell may be derived (derived) from a parent filamentous fungal cell, where the modified cell contains at least one genetic modification not found in the parent cell.

[0174] As used herein, a "functional gene" is a gene that can be used by cellular constituents to produce an active gene product, i.e., typically a protein. In contrast, a "non-functional gene" cannot be used by cellular constituents to produce an active gene product (i.e., a functional protein) or has a reduced ability to be used by cellular constituents to produce an active gene product (i.e., a functional protein).

[0175] As used herein, a "functional protein" is a protein that has a function or activity, such as an enzymatic function / activity, a binding function / activity (e.g., DNA binding), a surface active property, etc., and that has not been mutated, truncated, or otherwise altered to eliminate or reduce that function / activity.

[0176] As used herein, a "regulatory gene" is a gene whose function affects the production of a protein by a fungal host. In certain aspects of the disclosure, overexpression of a regulatory gene (encoding a regulatory protein) affects protein production by a filamentous fungal (host) cell. A "regulatory gene" encodes a "regulatory protein."

[0177] As used herein, "regulatory proteins" include, but are not limited to, transcription factor proteins, protein kinases, phosphatases, proteins involved in histone modification or chromatin remodeling, and similar functions associated with regulating gene or protein activity.

[0178] More specifically, as used herein, the terms "regulatory genes," "regulatory proteins," and / or other "gene transcription regulatory proteins" are not meant to be limiting, but rather are used herein to aid in classifying, characterizing, and / or identifying exemplary genes and / or proteins of the present disclosure. Thus, as further specified in Section III below and in the Examples below, the DNA and / or protein (PRT) sequences of the present disclosure are specifically referred to herein as regulatory genes and / or regulatory proteins, regardless of the overall protein function. For example, the regulatory proteins listed in Table 1, Table 10, and / or Table 16 may include proteins (e.g., enzymes) that are involved in one or more metabolic pathway activities, etc. (e.g., to relieve pathway bottlenecks, etc.), and such proteins (enzymes) may be referred to herein as regulatory proteins, regardless of the overall protein function.

[0179] As will be further detailed and described below, certain aspects of the present disclosure relate to genetic modifications that render mutant fungal cells defective in the production of one or more of the regulatory proteins of the present disclosure. More specifically, as described below in Examples 2-4 (see Table 1), mutant fungal cells defective in the production of one or more of the regulatory proteins of Table 1 include enhanced protein production characteristics / phenotypes (e.g., total protein production, enzyme activity, cellulose (PASC) hydrolysis, protein production rate, etc.).

[0180] As will be further detailed and described below, certain aspects of the present disclosure relate to the overexpression (overexpression) of certain regulatory genes encoding regulatory proteins. As used herein, "overexpression" (abbreviated "OE") of genes encoding regulatory proteins can be performed, for example, by introducing an additional copy (or multiple copies) of the particular gene encoding the regulatory protein into the fungal host, or by expressing the gene encoding the regulatory protein under the control of a heterologous promoter to increase expression of the gene, or by otherwise genetically modifying the fungal host so that the gene is more abundantly expressed and / or the activity of the gene product is increased. The effect of overexpression (OE) of genes encoding regulatory proteins can be studied by culturing the modified host under conditions suitable for protein production. The effect on the production of endogenous or heterologous proteins can be studied, for example, by determining the specific enzyme activity, by determining the amount of total protein, or by determining the amount of specific endogenous or heterologous protein produced.

[0181] More specifically, as described in Examples 5 and 6 (see Table 10), mutant fungal cells defective in the production of one or more regulatory proteins (presented in Table 10) include reduced protein production characteristics / phenotypes (e.g., total protein production, enzyme activity, cellulose (PASC) hydrolysis, protein production rate, etc.). Thus, as described and contemplated herein, in certain aspects, the present disclosure provides mutant fungal cells that, among other things, overexpress one or more regulatory proteins of Table 10.

[0182] As used herein, "gene disruption," "gene disruption," "gene inactivation," and "gene inactivation" are used interchangeably and refer broadly to any genetic modification that substantially prevents a host cell from producing a functional gene product (e.g., a functional protein). Exemplary methods of gene disruption include complete or partial deletion of any portion of a gene, including a polypeptide coding sequence, promoter, enhancer, or another regulatory element, or mutagenesis thereof (wherein mutagenesis encompasses substitutions, insertions, deletions, inversions, and any combinations and variations thereof that disrupt / inactivate the target gene and substantially reduce or inhibit production of a functional gene product (i.e., a functional protein).

[0183] As used herein, "gene deletion" refers to the removal of a gene from the genome of a host cell. In cases where a gene contains regulatory elements (e.g., enhancer elements) that are not located immediately adjacent to the coding sequence of the gene, gene deletion refers to the deletion of the coding sequence and, optionally, the deletion of adjacent enhancer elements, including, but not limited to, for example, promoter and / or terminator sequences.

[0184] As used herein, "heterologous gene" refers to a polynucleotide (DNA) sequence in which at least a portion of the sequence is non-native or present in a native form to the cell into which it is introduced and / or expressed.

[0185] As used herein, a "heterologous nucleic acid construct" or "heterologous DNA sequence" has a portion of the sequence that is not native or does not exist in a natural form to the cell in which it is expressed.

[0186] As used herein, a "heterologous protein" is encoded by a heterologous gene, heterologous nucleic acid (polynucleotide) sequence, heterologous DNA sequence, or the like.

[0187] Thus, in certain embodiments, a heterologous gene, heterologous nucleic acid construct, heterologous DNA sequence, etc., encoding a protein of interest (POI) is introduced (e.g., transformed) into a filamentous fungal cell (strain). For example, a heterologous gene construct encoding a POI can be introduced into a filamentous fungal cell (strain) before, during, or after other genetic modifications described herein.

[0188] Heterologous, in reference to a control sequence, refers to a control sequence (e.g., promoter, enhancer, terminator) that does not function in nature to regulate the same gene whose expression it currently regulates. Generally, heterologous nucleic acid sequences are not endogenous to the cell or part of the genome in which they are present, but have been added to the cell by infection, transfection, transformation, microinjection, electroporation, etc. A "heterologous" nucleic acid construct can contain a control sequence / DNA coding sequence combination that is identical to or different from the control sequence / DNA coding sequence combination found in the natural cell.

[0189] As used herein, the term "coding sequence" (abbreviated "CDS") refers to a polynucleotide sequence that directly specifies the amino acid sequence of its (encoded) protein product. The boundaries of a CDS are generally determined by an open reading frame (ORF), which usually begins with a start codon (ATG). Coding sequences generally include DNA, cDNA, and recombinant nucleotide sequences. For example, an ORF generally refers to a polynucleotide sequence (whether naturally occurring, non-naturally occurring, or synthetic) that includes a continuous reading frame consisting of (i) an initiation codon, (ii) a series of codons representing the amino acids of the encoded protein product, and (iii) a stop codon, and that is read (or translated) in a 5' to 3' direction.

[0190] As used herein, the term "DNA construct" or "expression construct" refers to a nucleic acid sequence comprising at least two DNA polynucleotide fragments. The DNA or expression construct can be used to introduce a nucleic acid sequence into a fungal host cell. The DNA can be generated in vitro (e.g., by PCR) or by any other suitable technique. In some embodiments, the DNA construct comprises a sequence of interest (e.g., encoding a protein of interest). In certain embodiments, the polynucleotide sequence of interest is operably linked to a promoter and / or a terminator. In some embodiments, the DNA construct further comprises at least one selectable marker. In further embodiments, the DNA construct comprises a sequence homologous to a host cell chromosome. In other embodiments, the DNA construct comprises a sequence heterologous to a host cell chromosome.

[0191] As used herein, "flanking sequence" refers to any sequence that is upstream or downstream of the sequence under consideration (e.g., in gene ABC, gene B is flanked by gene sequences A and C). In certain embodiments, the incoming sequence is flanked on both sides by homology boxes. In yet other embodiments, the incoming sequence and homology box comprise a unit that is flanked on both sides by stuffer sequences. In some embodiments, the flanking sequences are present on only one side (3' or 5'), but in preferred embodiments, they are present on both sides of the sequence that they are flanking. The sequence of each homology box is homologous to a sequence in a filamentous fungal chromosome. These sequences direct where in the filamentous fungal chromosome the new construct will be integrated and what, if any, part of the chromosome will be replaced by the incoming sequence.

[0192] As used herein, the term "downregulation" of gene expression includes any method that results in lower (downregulated) expression of a functional gene product.

[0193] The term "vector" is defined herein as a polynucleotide designed to carry a nucleic acid sequence for introduction into one or more cell types. Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, phage or viral particles, DNA constructs, cassettes, etc. Expression vectors can include regulatory sequences such as promoters, signal sequences, coding sequences, and transcription terminators.

[0194] As used herein, "expression vector" refers to a DNA construct containing a coding sequence operably linked to suitable control sequences capable of effecting the expression of a protein in a suitable host. Such control sequences may include a promoter to effect transcription, an optional operator sequence to control transcription, a sequence encoding suitable ribosome binding sites on the mRNA, an enhancer, and sequences that control the termination of transcription and translation.

[0195] As used herein, the term "secretory signal sequence" refers to a DNA sequence that encodes a polypeptide (i.e., a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through the secretory pathway of the cell in which it is synthesized. The larger polypeptide is normally cleaved during passage through the secretory pathway to remove the secretory peptide.

[0196] As used herein, the terms "isolated" or "purified" refer to a filamentous fungal cell, nucleic acid or polypeptide that has been removed from at least one component with which it is naturally associated.

[0197] As used herein, the term "protein of interest" or "POI" refers to a polypeptide that is desired to be expressed in a filamentous fungal cell. Such proteins may be enzymes, substrate binding proteins, surface active proteins, structural proteins, etc., and may be expressed at high levels and may be intended for commercialization. For example, as generally described below, POIs include cellulases, hemicellulases, xylanases, peroxidases, proteases, lipases, phospholipases, esterases, cutinases, polyesterases, pectinases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, mannanases, α-glucanases, β-glucanases, hyaluronidases, chondroitinases, laccases, and the like. , amylase, glucoamylase, acetyl esterase, aminopeptidase, arabinase, arabinosidase, arabinosidase, arabinofuranosidase, carboxypeptidase, catalase, nuclease, deoxyribonuclease, ribonuclease, epimerase, α-galactosidase, β-galactosidase, glucan lyase, endo-β-glucanase, glucose oxidase, glucuronidase, invertase, isomerase, and the like.

[0198] The protein of interest (POI) may be encoded by an "endogenous" gene. For example, in certain embodiments, the POI is encoded by a gene endogenous to the filamentous fungal cell (strain), such as the wild-type genes encoding naturally occurring cellulases (e.g., cellobiohydrolases, xylanases, endoglucanases, and β-glucosidases) described above.

[0199] As used herein, the term "increased production" and variations thereof refers to an increase of at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, or at least 20% (e.g., greater than 20%) in the production of a protein of interest by an engineered (mutated) filamentous fungal cell overexpressing a regulatory gene encoding a regulatory protein of the present disclosure when cultured under the same conditions of medium composition, temperature, pH, cell density, dissolved oxygen, and other conditions as a parent (control) filamentous fungal cell that does not overexpress the regulatory protein.

[0200] As used herein, when a recombinant cell is used in phrases such as "produces an 'increased amount' of a protein of interest," the term "increased amount" and variations thereof means an increase of at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, or at least 20% (e.g., more than 20%) in the amount of the protein of interest produced by an engineered (mutated) filamentous fungal cell overexpressing a regulatory gene encoding a regulatory protein of the present disclosure when cultured under the same conditions of medium composition, temperature, pH, cell density, dissolved oxygen, and the like as a parent (control) filamentous fungal cell that does not overexpress the regulatory protein.

[0201] As used herein, the terms "polypeptide" and "protein" (and / or their respective plurals) are used interchangeably and refer to polymers of any length comprising amino acid residues linked by peptide bonds. Conventional one-letter or three-letter codes for amino acid residues are used herein. The polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. These terms also encompass amino acid polymers that are modified naturally or by intervention (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component). Also included within the scope of this definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.

[0202] As used herein, functionally and / or structurally similar proteins are considered to be "related proteins". Such proteins may be from organisms of different genera and / or species, or from different classifications of organisms (e.g., bacteria and fungi). Related proteins also encompass homologs as determined by primary sequence analysis, by secondary or tertiary structure analysis, or by immunological cross-reactivity.

[0203] As used herein, the phrase "substantially free of activity," or similar phrases, means that the particular activity cannot be detected in the mixture or is present in an amount that does not interfere with the intended purpose of the mixture.

[0204] As used herein, the term "derived polypeptide" refers to a protein that is obtained or can be obtained from a protein by the addition of one or more amino acids to either or both of the N-terminus and C-terminus, the substitution of one or more amino acids at one or many different sites in the amino acid sequence, the deletion of one or more amino acids at one or both termini of the protein or at one or more sites in the amino acid sequence, and / or the insertion of one or more amino acids at one or more sites in the amino acid sequence. Preparation of a protein derivative can be accomplished by modifying a DNA sequence encoding the native protein, transforming the DNA sequence into a suitable host, and expressing the modified DNA sequence to form a derived protein.

[0205] Related (and derived) proteins include "mutated proteins." Mutant proteins differ from a reference / parent protein (e.g., a wild-type protein) by substitutions, deletions, and / or insertions at a small number of amino acid residues. The number of different amino acid residues between a mutant protein and a parent protein can be one or more, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more amino acid residues. A mutant protein can share at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% or more amino acid sequence identity with a reference protein. A mutant protein may also differ from a reference protein in selected motifs, domains, epitopes, conserved regions, etc.

[0206] As used herein, the term "homologous" protein refers to a protein that has a similar activity, function and / or structure as a reference protein. Homologs are not necessarily evolutionarily related. Thus, the term is intended to encompass identical, similar, or corresponding proteins (i.e., with respect to structure and function) obtained from different organisms. In some embodiments, it is desirable to identify homologs that have a similar quaternary, tertiary, and / or primary structure to the reference protein. For example, regulatory protein homologs from Aspergillus niger, Aspergillus oryzae, and / or Thermothelomyces thermophilus (i.e., containing substantial amino acid sequence identity to the full-length T. reesei regulatory protein of the present disclosure) are described in Example 10 (see Table 6).

[0207] The degree of homology between sequences may be determined using any suitable method known in the art (see, for example, Smith and Waterman, 1981; Needleman and Wunsch, 1970; Pearson and Lipman, 1988; programs such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI); and Devereux et al., 1984). For purposes of the present invention, the degree of identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970) as implemented in the Needle program of the EMBOSS package (Rice et al., 2000), preferably version 3.0.0 or later. Optional parameters used may include a gap open penalty of 10, a gap extension penalty of 0.5, and an EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of the needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity, calculated as follows: (Identical residues × 100) / (length of alignment – ​​total number of gaps in alignment)

[0208] For the purposes of the present invention, the degree of identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (Rice et al., 2000, supra), preferably version 3.0.0 or later. Optional parameters used are a gap open penalty of 10, a gap extension penalty of 0.5, and an EDNAFULL (the EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: (identical deoxyribonucleotides × 100) / (length of alignment – ​​total number of gaps in alignment)

[0209] As used herein, the phrases "substantially similar" and "substantially identical," in the context of at least two nucleic acids or polypeptides, generally mean that the polynucleotide or polypeptide comprises a sequence having at least about 40% identity, at least about 50% identity, at least about 60% identity, at least about 70% identity, at least about 75% identity, at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, or even at least about 99% identity or more, compared to a reference (i.e., wild-type) sequence. Sequence identity can be determined using known programs such as BLAST, ALIGN, and CLUSTAL, using standard parameters.

[0210] As used herein, the terms "inducer", "inducers" or "inducing substrate" are used interchangeably and refer to any compound that causes a filamentous fungal cell to produce "increased amounts" of total protein. Examples of inducing substrates include, but are not limited to, sophorose, lactose, gentibiose, and cellulose.

[0211] As used herein, the term "induction" refers to an increase in transcription of a gene that results in the synthesis of a protein of interest in a filamentous fungal cell at a significantly greater rate in response to the presence of an "inducer" (i.e., an inducing substrate).

[0212] To measure "induction" of a gene of interest (GOI) encoding a protein of interest (POI), modified filamentous fungal cells are supplemented with a candidate induction substrate (inducer) and compared to parental filamentous fungal (control) cells supplemented with the same induction substrate (inducer). Thus, the parental (control) cells are assigned a relative protein activity value of 100%, and induction of the GOI encoding POI in modified host cells is achieved when the activity value (i.e., relative to the control cells) is greater than 100% (e.g., 100.1%-100.9%), greater than 101%, greater than 105%, greater than 110%, greater than 150%, greater than 200-500% (i.e., relative to the control), or greater.

[0213] As used herein, "aerobic fermentation" refers to growth in the presence of oxygen.

[0214] As used herein, the term "cell broth" collectively refers to the medium and cells in a liquid / submerged culture.

[0215] As used herein, the term "cell mass" refers to the cellular components (including intact and lysed cells) present in a liquid / submerged culture. Cell mass can be expressed as dry weight or wet weight.

[0216] As used herein, the phrase "high temperature fermentation (cultivation) temperature" is a fermentation temperature that is higher than the standard fermentation conditions described in the Examples.

[0217] It will be understood that the methods of the present disclosure are not limited to a particular sequence for obtaining modified (mutated) filamentous fungal cells (strains). Genetic modifications can be introduced into the parent strain at any step in the construction of the strain for the production of an endogenous protein of interest (POI) and / or for the production of a heterologous POI.

[0218] III. Regulatory Proteins As generally understood by those skilled in the art, regulatory proteins are involved in the regulation of cellular homeostasis at various levels, including but not limited to the process of transcribing DNA into RNA. For example, many regulatory proteins, called transcription factors, are sequence-specific DNA-binding proteins that typically control, regulate, mediate, etc., the rate of gene transcription by binding to specific (target) sites in the promoter region of the (regulated) gene (Latchman, 1993). More specifically, one distinct feature of transcription factors is that they possess a DNA-binding domain (DBD) that gives them the ability to bind to specific sequences of DNA, called enhancer or promoter sequences. Thus, some regulatory proteins bind to DNA promoter sequences near the transcription start site and aid in the formation of the transcription initiation complex. Other regulatory proteins can bind to regulatory sequences, such as enhancer sequences, to stimulate or repress the transcription of the associated gene, and these regulatory sequences can be several thousand base pairs (bp) upstream (5') or downstream (3') of the gene to be transcribed.

[0219] Protein kinases are regulatory proteins that can selectively modify (i.e., phosphorylate) other proteins by (covalently) adding phosphates to them. Histone acetylases / deacetylases are regulatory proteins that can modify histone proteins through the covalent addition / removal of acetyl groups (COCH3), respectively. For example, regulation of transcription is the most common form of gene control, and the action of regulatory proteins allows for unique spatiotemporal regulation of gene expression patterns.

[0220] The production of cellulases, hemicellulases, ligninases, pectinases, etc. is believed to be regulated mainly at the transcriptional level in filamentous fungi (Aro et al., 2005). For example, Stricker et al., (2008) described the similarities and differences in the transcriptional regulation of cellulase and hemicellulase expression in Aspergillus niger and Trichoderma reesei, including the action of XlnR and Xyr1. As described by Kubicek et al. (2009), several regulatory components are involved in cellulase regulation in T. reesei, either positively (Xyr1, Ace2, Hap2 / 3 / 5) or negatively (Ace1, Cre1). Although the action of several regulatory genes on protein production has been described, there is still a need for improved filamentous fungal strains that can enhance the production of endogenous and heterologous proteins of interest.

[0221] As is generally known in the art, filamentous fungal strains are typically grown as submerged mycelium cultures in bioreactors adapted to, among other things, introduce and distribute oxygen and nutrients to the culture medium (i.e., fermentation broth) and maintain optimal pH and temperature. In particular, the power required to mix, aerate, cool, etc. the fermentation broth can significantly increase production costs and lead to higher capital expenditures in terms of motors, power supplies, cooling equipment, etc. For example, heat generation during the fermentation process is closely related to the utilization of carbon and energy sources (Wang et al., 1979). As generally described by Wang et al. (1979), the amount of heat is related to the stoichiometry of growth and product formation, but the rate of heat generation is proportional to the kinetics of the process, and interest in heat generation arises from the need to remove it during the fermentation process (e.g., to maintain optimal product formation). Thus, running the process at a higher temperature can be beneficial as it can shorten the fermentation time and release fermentation capacity.

[0222] Generally, most filamentous fungi grow and efficiently produce proteins or other metabolic products only within a temperature range of about 20°C to 40°C. For example, while fermentation temperatures may vary somewhat, for filamentous fungi such as Trichoderma reesei, the temperatures are generally within the range of about 20°C to 40°C, and generally preferably within the range of about 25°C to 34°C. Thus, the ability to ferment filamentous fungal strains at elevated temperatures for the production of proteins is of particular interest in reducing the time and cost of protein production. As described below, the mutant fungal cells (strains) of the present disclosure are well suited for use in industrial-scale fermentation processes to enhance production of proteins of interest.

[0223] More specifically, as described herein and in the Examples section below, Applicant first identified over 400 predicted regulatory proteins via bioinformatics tools using wild-type Trichoderma reesei QM6a strain (ATCC No. 13631) from the JGI database (Nordberg et al., 2014). As described in Example 1, Applicant created a library of regulatory protein deletion constructs (by fusion PCR) in which a total of 343 regulatory protein deletion (deficient) strains were obtained and screened for improved properties. Applicant further screened the 343 regulatory protein deletion strains for changes in protein production properties / phenotypes (e.g., total protein production, enzyme activity, cellulose (PASC) hydrolysis, protein production rate, etc.). More specifically, as described in the Examples section (see Examples 2-4), T. reesei regulatory protein deletion strains with improved protein production phenotypes under certain conditions are shown in Tables 2-9 below.

[0224] As further described in the Examples section, mutant fungal strains defective in the production of one or more regulatory proteins in Table 10 comprise a reduced protein production characteristic / phenotype under the conditions specified in Examples 5 and 6 (Tables 11-15). Thus, in certain aspects, the present disclosure relates to mutant fungal strains that overexpress one or more regulatory proteins in Table 10, where the OE mutants comprise an improved protein production phenotype under the specified conditions.

[0225] In certain aspects, the parental fungal strain comprises a naturally occurring gene encoding a regulatory protein that comprises at least about 50% or more sequence identity, at least about 55% or more sequence identity, at least about 60% or more sequence identity, at least about 65% or more sequence identity, or at least about 70% or more sequence identity to a regulatory protein set forth in Table 1, Table 10, and / or Table 16, or a DNA binding domain (DBD) subsequence thereof. In certain embodiments, the parental fungal cell comprises a functional regulatory protein that comprises about 70%-99% amino acid sequence identity to a regulatory protein set forth in Table 1, Table 10, and / or Table 16, or a DBD subsequence thereof.

[0226] As generally described in Example 7, fungal regulatory protein homologs from Aspergillus niger, Aspergillus oryzae, and Myceliophthora thermophila are shown in Table 16. In certain embodiments, a regulatory protein of the disclosure comprises at least about 50% or more sequence identity (e.g., about 51-99% identity or 100% identity) to a regulatory protein homolog shown in Table 16.

[0227] Thus, in certain embodiments, the parent fungal strain comprises a naturally occurring gene encoding a regulatory protein that comprises at least about 50% or more sequence identity, at least about 55% or more sequence identity, at least about 60% or more sequence identity, at least about 65% or more sequence identity, or at least about 70% or more sequence identity to a regulatory protein set forth in any one of Tables 1-16, or a DNA binding domain (DBD) subsequence thereof.

[0228] In certain embodiments, the parent fungal cell comprises a functional regulatory protein that comprises about 70%-99% amino acid sequence identity to a regulatory protein listed in any one of Tables 1-16, or a DBD subsequence thereof.

[0229] In certain embodiments, the polynucleotide sequences (or subsequences thereof) of the present disclosure, and / or the protein sequences (or subsequences thereof) of the present disclosure and / or DNA binding domain (DBD) subsequences thereof, or fragments thereof, can be used to design nucleic acid probes for identifying and cloning DNA (polynucleotides) encoding regulatory proteins from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with genomic DNA or cDNA of fungal cells of interest according to standard Southern blotting procedures in order to identify and isolate the corresponding genes therein.

[0230] Such probes may be much shorter than the entire sequence, but must be at least 15, e.g., at least 25, at least 35, or at least 70 nucleotides long. Preferably, the nucleic acid probe is at least 100 nucleotides long, e.g., at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, or at least 900 nucleotides long. Both DNA and RNA probes can be used. These probes are usually labeled (e.g., with 32P, 3H, 35S, biotin, or avidin) to detect the corresponding gene. Thus, genomic DNA or cDNA libraries prepared from such other strains can be screened for DNA that hybridizes with the above-mentioned probes and codes for regulatory proteins. Genomic DNA or other DNA from such other strains can be separated by agarose or polyacrylamide gel electrophoresis or other separation techniques. DNA from the library or the separated DNA can be transferred and immobilized on nitrocellulose or other suitable carrier materials. The carrier material is used in a Southern blot to identify clones or DNA which hybridize to SEQ ID NO:1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, or 79, or a subsequence thereof.

[0231] Accordingly, certain embodiments relate to mutant fungal strains derived from a parent fungal strain that contains a naturally occurring gene encoding one or more functional regulatory proteins comprising an amino acid sequence comprising at least about 50% identity to one or more fungal regulatory proteins disclosed herein, where the gene encoding the regulatory protein has been genetically modified as described herein, thereby rendering the mutant fungal cell defective (i.e., relative to the parent cell) in the production of the one or more functional regulatory proteins. In a related aspect, the mutant fungal strains of the present disclosure (defective in the production of one or more functional regulatory proteins) produce increased amounts of a protein of interest relative to the parent fungal strain when cultured under the same conditions.

[0232] As generally shown in Tables 1 and 10 below, a DNA binding domain (DBD) is an amino acid (subsequence) present in the primary (1°) amino acid sequence of a full-length regulatory protein. However, the specific DBD amino acid subsequences presented herein are not meant to be limiting, but rather to provide exemplary amino acid subsequences (i.e., DBD domains / motifs) suitable for the genetic modifications described herein. For example, as contemplated and described herein, regulatory proteins are typically sequence-specific DNA binding proteins that control, regulate, mediate, etc., the rate of gene transcription by binding to specific (target) sites (i.e., DBDs) in the promoter region of the (regulated) gene. Thus, in certain embodiments, a mutant strain is derived / obtained from a parent fungal strain, and the mutant strain comprises a genetic modification that disrupts, deletes, or otherwise mutates the DBD of one or more regulatory proteins (see Table 1), thereby rendering the mutant strain defective (relative to the parent strain) in the production of one or more regulatory proteins. In certain other embodiments, the mutant cell is derived / obtained from a parent fungal strain, and the mutant strain comprises an introduced nucleic acid (e.g., an expression cassette) that overexpresses one or more regulatory proteins set forth in Table 10. For example, in certain embodiments, the mutant cell comprises an introduced expression cassette encoding one or more copies of one or more functional regulatory proteins (i.e., relative to the parent strain). In related aspects, the mutant fungal cell of the present disclosure is, inter alia, defective in the production of at least one regulatory protein of Table 1 and overexpresses at least one regulatory protein of Table 10.

[0233] IV. Recombinant Nucleic Acid and Molecular Biology As described in Section III above, certain aspects relate to mutant fungal strains derived from a parent strain that includes a native gene encoding one or more regulatory proteins of the present disclosure, where the mutant strain includes a genetic modification that renders the mutant strain defective in the production of one or more regulatory proteins encoded by the native gene. Certain other aspects relate to mutant fungal strains that include one or more introduced nucleic acids (e.g., expression cassettes) that overexpress one or more regulatory proteins of the present disclosure. In a related aspect, the mutant fungal strain includes a genetic modification that renders the mutant strain defective in the production of one or more regulatory proteins, and includes one or more introduced nucleic acids that overexpress one or more regulatory proteins of the present disclosure. In any of these embodiments, the mutant and / or parent strains may include additional genetic modifications as described herein.

[0234] In certain aspects, Applicant has screened over 300 regulatory protein deficient (mutant) strains for enhanced protein production traits / phenotypes (see Examples 1-4, Tables 2-9). In certain other aspects, Applicant has identified mutant fungal strains deficient in the production of one or more regulatory proteins, including reduced protein production traits / phenotypes under specified conditions (Table 10) (see Examples 5-6, Tables 11-15). In certain embodiments, the present disclosure provides mutant fungal strains that overexpress one or more regulatory proteins of Table 10, where the OE mutant strains include enhanced protein production traits / phenotypes (under certain conditions). Thus, certain embodiments relate to recombinant microbial strains, recombinant polynucleotides, plasmids, vectors, expression cassettes, and the like. In certain aspects, the mutant (recombinant) filamentous fungal strains described herein express one or more (heterologous or endogenous) proteins of interest.

[0235] As described briefly herein and in the Examples below, the present disclosure generally relies on routine techniques in the field of recombinant genetics, and the described recombinant polynucleotides, filamentous fungal strains, and the like can be constructed using routine methods known in the art (e.g., Sambrook et al., 1989; 2011; 2012; Kriegler 1990 and Ausubel et al., 1994).

[0236] Thus, in certain aspects, one or more genetic elements, such as promoter sequences, gene CDS, 5'-UTR sequences, vectors, polynucleotides, etc., may be genetically modified, as generally understood by those skilled in the art. In certain embodiments, genetic modifications include, but are not limited to, (a) the introduction, replacement or removal of one or more nucleotides in a gene, or the introduction, replacement or removal of one or more nucleotides in a regulatory element required for transcription or translation of a gene, (b) gene disruption, (c) gene conversion, (d) gene deletion, (e) gene downregulation, (f) gene overexpression (OE), (g) directed mutagenesis, and / or (h) random mutagenesis of any one or more genes disclosed herein.

[0237] In certain embodiments, modified (mutated) filamentous fungal cells can be constructed via CRISPR-Cas9 editing. For example, genes of interest can be modified, disrupted, deleted, or downregulated by nucleic acid-guided endonucleases that find their target DNA by binding to guide RNA (e.g., Cas9 and Cpf1) or guide DNA (e.g., NgAgo), which recruits endonucleases to target sequences on the DNA, and the endonucleases can generate single- or double-stranded breaks in the DNA. This targeted DNA break can become a substrate for DNA repair and recombine with the editing template provided to disrupt, delete, or modify the gene. For example, a gene encoding a nucleic acid-guided endonuclease (for this purpose, Cas9 from Streptococcus pyogenes) or a codon-optimized gene encoding a Cas9 nuclease is operably linked to a promoter active in fungal cells and a terminator active in fungal cells, thereby generating a fungal Cas9 expression cassette. Similarly, one or more target sites unique to a gene of interest can be easily identified by those skilled in the art. For example, to construct a DNA construct encoding a gRNA directed to a target site in a gene of interest, a variable targeting domain (VT) will include the nucleotides of the target site that are 5' to the (PAM) protospacer adjacent motif (NGG), which nucleotides are fused to DNA encoding the Cas9 endonuclease recognition domain for S. pyogenes Cas9 (CER). The combination of the DNA encoding the VT domain and the DNA encoding the CER domain thereby generates a DNA encoding a gRNA. Thus, a fungal cell expression cassette for a gRNA is created by operably linking the DNA encoding the gRNA to a promoter active in fungal cells and a terminator active in fungal cells.

[0238] In certain embodiments, the DNA break induced by the endonuclease is repaired / replaced with the incoming sequence. For example, to precisely repair the DNA break generated by the above-mentioned Cas9 expression cassette and gRNA expression cassette, a nucleotide editing template is provided so that the DNA repair mechanism of the cell can utilize the editing template. For example, about 500 bp 5' of the target gene can be fused to about 500 bp 3' of the target gene to generate an editing template, which is used by the fungal host's mechanism to repair the DNA break generated by the RNA-guided endonuclease (RGEN). Even shorter stretches of nucleotides in the form of double-stranded or single-stranded DNA can be used as editing templates.

[0239] The Cas9 expression cassette, the gRNA expression cassette and the editing template can be co-delivered into filamentous fungal cells using many different methods (e.g., PEG-mediated protoplast transformation, protoplast fusion, electroporation, biolistics). Transformed cells are screened by PCR amplification of the target gene using forward and reverse primers. These primers can amplify the wild-type locus or the modified locus that has been edited by RGEN.

[0240] Those skilled in the art are well aware of suitable methods for introducing polynucleotides into filamentous fungal cells (e.g., Aspergillus species, Trichoderma species, etc.), in which standard techniques for transforming filamentous fungi and culturing fungi (well known to those skilled in the art) are used to transform the fungal host cells of the present disclosure. Thus, methods for introducing DNA constructs or vectors into fungal host cells include transformation, electroporation, nuclear microinjection, transduction, transfection (e.g., lipofection-mediated and DEAE-dextrin-mediated transfection), incubation with calcium phosphate DNA precipitates, high-velocity gun using DNA-coated microparticles, gene gun or biolistic transformation, protoplast fusion, and other techniques. General transformation techniques are known in the art (see, for example, Ausubel et al., 1987, Sambrook et al., 2001 and 2012, and Campbell et al., 1989). Expression of heterologous proteins in Trichoderma has been described, for example, in U.S. Patent Nos. 6,022,725; 6,268,328; Harkki et al., 1991 and Harkki et al., 1989. For transformation of Aspergillus strains, see also Cao et al. (2000).

[0241] In other particular embodiments, the recombinant nucleic acid (or its polynucleotide expression cassette or its expression vector) further comprises one or more selectable markers. Selectable markers for use in filamentous fungi include, but are not limited to, alsl, amdS, hphB, pyr2, pyr4, pyrG, sucA trpC, argB, bleomycin resistance markers, blasticidin resistance markers, pyrithiamine resistance markers, neomycin resistance markers, adenine pathway genes, thymidine kinase markers, and the like. In particular embodiments, the selectable marker is pyr2, the components and methods of use of which are generally described in WO 2011 / 153449.

[0242] Generally, transformation of Trichoderma species cells usually takes place over a period of 10 5 ~10 7 / mL, especially 2 × 10 6 Permeabilized protoplasts or cells are used at a density of 100 μL / mL. These protoplasts or cells in a suitable solution (e.g., 1.2 M sorbitol and 50 mM CaCl2) are mixed with the desired DNA. Generally, a high concentration of polyethylene glycol (PEG) is added to the uptake solution. Additives such as dimethyl sulfoxide, heparin, spermidine, potassium chloride, etc. may also be added to the uptake solution to facilitate transformation. Similar procedures are available for other fungal host cells. See, for example, U.S. Patent Nos. 6,022,725 and 6,268,328, both of which are incorporated by reference.

[0243] In certain aspects, the mutant strain comprises a genetic modification that replaces (substitutes) the native promoter sequence of the endogenous gene encoding the native regulatory protein of the present disclosure with a heterologous promoter sequence. For example, in certain embodiments, the mutant strain comprises a knock-in heterologous promoter sequence that drives the expression of the endogenous gene encoding the native regulatory protein. In other aspects, the mutant strain comprises a knock-out (or mutated) native promoter sequence of the endogenous gene encoding the functional regulatory protein, thereby rendering the mutant strain defective in the production of the native regulatory protein.

[0244] In other aspects, the mutant (or modified) strain comprises one or more introduced nucleic acids that overexpress one or more regulatory proteins of the present disclosure. For example, in certain aspects, the mutant strain comprises an introduced polynucleotide (expression cassette) that comprises a heterologous promoter (pro) sequence upstream (5') and operably linked to a downstream (3') nucleic acid encoding a regulatory protein of the present disclosure. Heterologous promoter (pro) sequences suitable for driving expression or overexpression of a regulatory protein include any promoter sequence known to those of skill in the art, with particularly preferred promoters including any promoter sequence that can increase expression of the regulatory protein in a desired fungal cell. In related embodiments, the cassette may further comprise a downstream (3') transcription terminator sequence operably linked to a gene CDS.

[0245] For example, a regulatory gene expression cassette comprising an upstream promoter operably linked to a regulatory gene CDS is shown diagrammatically below (Scheme A), where the promoter [pro] and regulatory gene CDS [reg_gene] sequences are indicated by an operable "-" combination in the 5' to 3' direction.

[0246] Scheme A: 5'-[pro]-[reg_gene]-3' Similarly, a regulatory gene expression cassette comprising an upstream promoter operably linked to a regulatory gene CDS operably linked to a downstream terminator sequence is shown diagrammatically in Scheme B below, where the promoter [pro], regulatory gene CS [reg_gene] and terminator [term] sequences are shown in operable "-" combinations in the 5' to 3' direction.

[0247] Scheme B: 5'-[pro]-[reg_gene]-[term]-3' As shown in Scheme A or B, the promoter and / or terminator sequences are not intended to be limiting, but rather are selected to be functional in the desired fungal cell / strain. For example, the promoter sequence can be any nucleotide sequence that exhibits transcriptional activity in a filamentous fungal cell, including mutant / mutant promoters, truncated promoters, tandem promoters, hybrid promoters, synthetic promoters, inducible promoters, regulated promoters, conditional expression systems, and combinations thereof. In many cases, a suitable promoter can be obtained from a gene encoding an extracellular or intracellular polypeptide that is native or heterologous (foreign) to the filamentous fungal cell. Examples of promoters suitable for driving expression of one or more regulatory genes of the present disclosure include, but are not limited to, the Trichoderma reesei cDNA1 promoter, eno1 promoter, pdc1 promoter, pki1 promoter, tef1 promoter, rp2 promoter, and other T. reesei promoters described in Fitz et al. 2018 (incorporated herein by reference in its entirety), Aspergillus oryzae thiA promoter, A. nidulans gpdA promoter, etc.

[0248] In certain embodiments, the disclosure relates to the expression / production of one or more proteins of interest that are endogenous to a filamentous fungal host cell, while in other embodiments, the disclosure relates to the expression / production of one or more proteins of interest that are heterologous to a filamentous fungal host cell.

[0249] In certain embodiments, heterologous genes are cloned into intermediate vectors before being transformed into filamentous fungal (host) cells for expression. These intermediate vectors can be, for example, prokaryotic vectors, such as plasmids or shuttle vectors. Expression vectors / constructs usually contain a transcription unit or expression cassette that includes all the additional elements required for the expression of a heterologous sequence. For example, a typical expression cassette contains a 5' promoter operably linked to the heterologous nucleic acid sequence encoding the POI, and may further include sequence signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

[0250] In addition to a promoter sequence, the expression cassette may also contain a transcription termination region downstream of the structural gene to provide efficient termination. The termination region may be obtained from the same gene as the promoter sequence or from a different gene. Although any fungal terminator is likely to be functional in the present invention, preferred terminators include the following: Terminators derived from the Trichoderma cbhI gene, the Aspergillus nidulans trpC gene (Yelton et al., 1984; Mullaney et al., 1985), the Aspergillus awamori or Aspergillus niger glucoamylase gene (Nunberg et al., 1984; Boel et al., 1984), and / or the Mucor miehei carboxyl protease gene (EP 0 215 594).

[0251] The specific expression vector used to transport genetic information into cells is not particularly important. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells can be used. Standard bacterial expression vectors include bacteriophage lambda and M13, as well as plasmids such as pBR322-based plasmids, pSKF, pET23D, and fusion expression systems such as MBP, GST, and LacZ, as well as yeast 2μ plasmids and centromere yeast plasmids. Epitope tags, such as c-myc, can also be added to recombinant proteins to provide convenient isolation methods.

[0252] Elements that can be included in the expression vector can also include a replicon, a gene encoding antibiotic resistance to allow for selection of bacteria carrying the recombinant plasmid, or a unique restriction site in a non-essential region of the plasmid to allow for the insertion of heterologous sequences. The particular antibiotic resistance gene selected is not critical, as any of a number of resistance genes known in the art can be suitable. Prokaryotic sequences are preferably selected so as not to interfere with DNA replication or integration in the fungal host.

[0253] The transformation methods of the present disclosure may result in stable integration of all or part of the transformation vector into the genome of the filamentous fungus. However, transformation resulting in the maintenance of an autonomously replicating extrachromosomal transformation vector is also contemplated. Any of the known procedures for introducing foreign (heterologous) nucleotide sequences into a host cell may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, biolistics, liposomes, microinjection, and any other method known for introducing cloned genomic DNA, cDNA, synthetic DNA, or other foreign genetic material into a host cell (see, for example, Sambrook et al., supra). Agrobacterium-mediated transfection methods, such as those described in U.S. Pat. No. 6,255,115, are also useful.

[0254] After the expression vector is introduced into the cells, the transfected cells are cultured under conditions that promote expression of the gene under the control of the cellulase gene promoter sequence. Large batches of transformed cells can be cultured as described herein. Finally, the product is harvested from the culture using standard techniques.

[0255] V. Protein of interest As mentioned above, certain embodiments relate to genetically mutated and / or modified (recombinant) fungal cells that contain a genetic modification to express a gene encoding a protein of interest (POI). More specifically, certain embodiments relate to compositions and methods for the expression / production of such proteins of interest in the modified (mutated) fungal cells of the present disclosure. Thus, in certain embodiments, the recombinant fungal cells have increased amounts of a protein of interest, including but not limited to enzymes, antibodies, receptor proteins, animal feed proteins, human food protein biologics, and the like.

[0256] In certain aspects, the protein of interest comprises an enzyme, hi certain embodiments, the protein of interest is an enzyme selected from the group consisting of amylase, cellulase, hemicellulase, xylanase, peroxidase, protease, lipase, phospholipase, esterase, cutinase, polyesterase, phytase, pectinase, keratinase, reductase, oxidase, phenoloxidase, lipoxygenase, ligninase, pullulanase, tannase, pentosanase, mannanase, α-glucanase, β-glucanase, hyaluronidase, chondroitinase, lacquer ... The enzyme is selected from the group consisting of enzymes such as ribonuclease, amylase, glucoamylase, acetyl esterase, aminopeptidase, arabinase, arabinosidase, arabinosidase, arabinofuranosidase, carboxypeptidase, catalase, nuclease, deoxyribonuclease, ribonuclease, epimerase, α-galactosidase, β-galactosidase, glucan lyase, endo-β-glucanase, glucose oxidase, glucuronidase, invertase, and isomerase.

[0257] The protein of interest (POI) can be an endogenous POI or a heterologous POI.

[0258] In certain embodiments, the POI is selected from an Enzyme Commission (EC) number selected from the group consisting of EC1, EC2, EC3, EC4, EC5 or EC6.

[0259] For example, in certain embodiments, the POI may be in the EC 1.10.3.2 (e.g., laccase), EC 1.10.3.3 (e.g., L-ascorbate oxidase), EC 1.1.1.1 (e.g., alcohol dehydrogenase), EC 1.11.1.10 (e.g., chloride peroxidase), EC 1.11.1.17 (e.g., peroxidase), EC 1.1.1.27 (e.g., L-lactate dehydrogenase), EC 1.1.1.28 (e.g., L-lactate dehydrogenase), EC 1.1.1.29 (e.g., L-lactate dehydrogenase), EC 1.1.1.30 (e.g., L-lactate dehydrogenase), EC 1.1.1.31 (e.g., L-lactate dehydrogenase), EC 1.1.1.32 (e.g., L-lactate dehydrogenase), EC 1.1.1.33 (e.g., L-lactate dehydrogenase), EC 1.1.1.34 (e.g., L-lactate dehydrogenase), EC 1.1.1.35 (e.g., L-lactate dehydrogenase), EC 1.1.1.36 (e.g., L-lactate dehydrogenase), EC 1.1.1.37 (e.g., L-lactate dehydrogenase), EC 1.1.1.38 (e.g., L-lactate dehydrogenase), EC 1.1.1.39 (e.g., L-lactate dehydrogenase), EC 1.1.1.40 (e.g., L-lactate dehydrogenase), EC EC 1.1.47 (e.g. glucose 1-dehydrogenase), EC 1.1.3.X (e.g. glucose oxidase), EC 1.1.3.10 (e.g. pyranose oxidase), EC 1.13.11.X (e.g. dioxygenase), EC 1.13.11.12 (e.g. linoleic acid l3S-lipoxygenase), EC 1.1.3.13 (e.g. alcohol oxidase) , EC 1.14.14.1 (e.g., monooxygenases), EC 1.14.18.1 (e.g., monophenol monooxygenases), EC 1.15.1.1 (e.g., superoxide dismutases), EC 1.1.5.9 (formerly EC 1.1.99.10, e.g., glucose dehydrogenases), EC 1.1.99.18 (e.g., cellobiose dehydrogenases), EC 1.1.99.29 (e.g., pyranolases), and EC 1 enzymes (oxidoreductases) selected from EC 1.1.1.1 (e.g., ester dehydrogenase), EC 1.2.1X (e.g., fatty acid reductase), EC 1.2.1.10 (e.g., acetaldehyde dehydrogenase), EC 1.5.3.X (e.g., fructosylamine reductase), EC 1.8.1X (e.g., disulfide reductase), and EC 1.8.3.2 (e.g., thiol oxidase).

[0260] In certain embodiments, the POI is selected from the group consisting of EC 2.3.2.13 (e.g., transglutaminase), EC 2.4.1X (e.g., hexosyltransferase), EC 2.4.1.40 (e.g., artemasclase), EC 2.4.1.18 (e.g., 1,4 alpha-glucan branching enzyme), EC 2.4.1.19 (e.g., cyclomaltodextrin glucanotransferase), EC 2.4.1.2 (e.g., dextrin dextranase), EC 2.4.1.20 (e.g., cellobiose phosphorylase), EC 2.4.1.25 (e.g., 4-alpha-glucanotransferase), EC 2.4.1.333 (e.g., 1,2-beta-oligoglucan phosphotransferase), E and EC 2.7.9.4 (e.g., alpha glucan kinase) and EC 2.7.9.5 (e.g., phosphoglucan kinase).

[0261] In other embodiments, the POI is selected from the group consisting of EC 3.1.XX (e.g., esterases), EC 3.1.1.1 (e.g., pectinases), EC 3.1.1.14 (e.g., chlorophyllases), EC 3.1.1.20 (e.g., tannases), EC 3.1.1.23 (e.g., glycerol ester acyl hydrolases), EC 3.1.1.26 (e.g., galactolipases), EC 3.1.1.32 (e.g., phospholipase A1), EC 3.1.1.4 (e.g., phospholipase A2), EC 3.1.1.6 (e.g., acetyl esterases), E C3.1.1.72 (e.g., acetyl xylan esterase), EC 3.1.1.73 (e.g., feruloyl esterase), EC 3.1.1.74 (e.g., cutinase), EC 3.1.1.86 (e.g., rhamnogalacturonan acetyl esterase), EC 3.1.1.87 (e.g., fumosin B1 esterase), EC 3.1.26.5 (e.g., ribonuclease P), EC 3.1.3.X (e.g., phosphate monoester hydrolase), EC 3.1.30.1 (e.g., Aspergillus nuclease), EC 3.1.3.1 (e.g., Serratia marcescens nuclease), EC 3.1.3.1 (e.g., alkaline phosphatase), EC 3.1.3.2 (e.g., acid phosphatase), EC 3.1.3.8 (e.g., 3-phytase), EC 3.1.4.1 (e.g., phosphodiesterase I), EC 3.1.4.11 (e.g., phosphoinositide phospholipase C), EC 3.1.4.3 (e.g., phospholipase C), EC 3.1.4.4 (e.g., phospholipase D), EC 3.1.6.1 (e.g., arylsulfa EC 3.1.8.2 (e.g. diisopropyl fluorophosphatase), EC 3.2.1.10 (e.g. oligo-1,6-glucosidase), EC 3.2.1.101 (e.g. mannan endo-1,6-alpha-mannosidase), EC 3.2.1.11 (e.g. alpha-1,6-glucan-6-glucanohydrolase), EC 3.2.1.131 (e.g. xylan alpha-1,2-glucuronosidase), EC 3.2.1.132 (e.g. chitosan N-acetylglucosaminohydrolase), EC 3.2.1.139 (e.g., alpha-glucuronidase), EC 3.2.1.14 (e.g., chitinase), EC 3.2.1.151 (e.g., xyloglucan-specific endo-beta-1,4-glucanase), EC 3.2.1.155 (e.g., xyloglucan-specific exo-beta-1,4-glucanase), EC 3.2.1.164 (e.g., galactan endo-1,6-beta-galactosidase), EC 3.2.1.17 (e.g., lysozyme), EC 3.2.1.171 (e.g., rhamnogalacturonan hydrolase), EC 3.2.1.174 (e.g., For example, rhamnogalacturonan rhamnohydrolase), EC 3.2.1.2 (e.g., beta amylase), EC 3.2.1.20 (e.g., alpha-glucosidase), EC 3.2.1.22 (e.g., alpha-galactosidase), EC 3.2.1.25 (e.g., beta-mannosidase), EC 3.2.1.26 (e.g., beta-fructofuranosidase), EC 3.2.1.37 (e.g., xylan 1,4-beta-xylosidase), EC 3.2.1.39 (e.g., glucan endo-1,3-beta-D-glucosidase), EC 3.2. EC 3.2.1.50 (e.g., alpha-L-rhamnosidase), EC 3.2.1.51 (e.g., alpha-L-fucosidase), EC 3.2.1.52 (e.g., beta-N-acetylhexosaminidase), EC 3.2.1.55 (e.g., alpha-N-arabinofuranosidase), EC 3.2.1.58 (e.g., glucan 1,3-beta-glucosidase), EC 3.2.1.59 (e.g., glucan endo-1,3-alpha-glucosidase), EC 3.2.1.67 (e.g., galacturan 1,4-alpha-galacturonidase), EC 3.2. EC 3.2.1.1.68 (e.g. isoamylase), EC 3.2.1.7 (e.g. 1-beta-D-fructan fructanohydrolase), EC 3.2.1.74 (e.g. glucan 1,4-glucosidase), EC 3.2.1.75 (e.g. glucan endo-1,6-beta-glucosidase), EC 3.2.1.77 (e.g. mannan 1,2-(1,3)-alpha-mannosidase), EC 3.2.1.80 (e.g. fructan beta-fructosidase), EC 3.2.1.82 (e.g. exopoly alpha-galacturonosidase), EC 3.2.1.83 (e.g., kappa-carrageenase), EC 3.2.1.89 (e.g., arabinogalactan endo-1,4-beta-galactosidase), EC 3.2.1.91 (e.g., cellulose 1,4-beta-cellobiosidase), EC 3.2.1.96 (e.g., mannosylglycoprotein endo-beta-N-acetylglucosaminidase), EC 3.2.1.99 (e.g., arabinan endo-1,5-alpha-L-arabinanase), EC 3.4.XX (e.g., peptidases), EC 3.4.11.X (e.g., aminopeptidases), EC 3.4 EC 3.4.11.1 (e.g., leucyl aminopeptidase), EC 3.4.11.18 (e.g., methionyl aminopeptidase), EC 3.4.13.9 (e.g., Xaa-Pro dipeptidase), EC 3.4.14.5 (e.g., dipeptidyl peptidase IV), EC 3.4.16.X (e.g., serine-type carboxypeptidase), EC 3.4.16.5 (e.g., carboxypeptidase C), EC 3.4.19.3 (e.g., pyroglutamyl peptidase I), EC 3.4.21.X (e.g., serine endopeptidase), EC 3.4.21.1 (e.g., chymotrypsin), EC 3.4.21.19 (e.g., glutamyl endopeptidase), EC 3.4.21.26 (e.g., prolyl oligopeptidase), EC 3.4.21.4 (e.g., trypsin), EC 3.4.21.5 (e.g., thrombin), EC 3.4.21.63 (e.g., oryzen), EC 3.4.21.65 (e.g., thermomycolin), EC 3.4.21.80 (e.g., streptoglycin A), EC 3.4.22.X (e.g., cysteine ​​endopeptidase), EC 3.4.22.14 (e.g., actinida EC 3.4.22.2 (e.g., papain), EC 3.4.22.3 (e.g., phycan), EC 3.4.22.32 (e.g., stem bromelain), EC 3.4.22.33 (e.g., fruit bromelain), EC 3.4.22.6 (e.g., chymopapain), EC 3.4.23.1 (e.g., pepsin A), EC 3.4.23.2 (e.g., pepsin B), EC 3.4.23.22 (e.g., endothiapepsin), EC 3.4.23.23 (e.g., mucorpepsin), EC 3.4.23.3 (e.g., gastricsin), EC 3.4.24.X (e.g., metalloendopeptidase), EC 3.4.24.39 (e.g., deuterolysin), EC 3.4.24.40 (e.g., serralysin), EC 3.5.1.1 (e.g., asparaginase), EC 3.5.1.11 (e.g., penicillin amidase), EC 3.5.1.14 (e.g., N-acyl fatty-L-amino acid amidohydrolase), EC 3.5.1.2 (e.g., L-glutamine amidohydrolase), EC 3.5.1.28 (e.g., N-acetylmuramoyl-L-alanine amidase), EC 3.5.1.4 (e.g., amidase) , hydrolases including EC 3 (hydrolase) enzymes selected from EC 3.5.1.44 (e.g., protein-L-glutamine amidohydrolase), EC 3.5.1.5 (e.g., urease), EC 3.5.1.52 (e.g., peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase), EC 3.5.1.81 (e.g., N-acyl-D-amino acid deacylases), EC 3.5.4.6 (e.g., AMP deaminase) and EC 3.5.5.1 (e.g., nitrilase).

[0262] In other embodiments, the POI is a lyase enzyme, including but not limited to an EC 4 (lyase) enzyme selected from EC 4.1.2.10 (e.g., mandelonitrile lyase), EC 4.1.3.3 (e.g., N-acetylneuraminic acid lyase), EC 4.2.1.1 (e.g., carbonic anhydrase), EC 4.2.2.- (e.g., rhamnogalacturonan lyase), EC 4.2.2.10 (e.g., pectin lyase), EC 4.2.2.22 (e.g., pectate trisaccharide lyase), EC 4.2.2.23 (e.g., rhamnogalacturonan endolyase), and EC 4.2.2.3 (e.g., mannuronate-specific alginate lyase).

[0263] In certain other embodiments, the POI is an isomerase enzyme, including but not limited to an EC 5 (isomerase) enzyme selected from EC 5.1.3.3 (e.g., aldose 1-epimerase), EC 5.1.3.30 (e.g., D-psicose 3-epimerase), EC 5.4.99.11 (e.g., isomaltulose synthase), and EC 5.4.99.15 (e.g., (1 4)-aD-glucan 1-aD-glucosylmutase).

[0264] In yet other embodiments, the POI is a ligase enzyme, including but not limited to an EC6 (ligase) enzyme selected from EC 6.2.1.12 (e.g., 4-coumarate:coenzyme A ligase) and EC 6.3.2.28 (e.g., L-amino acid alpha-ligase).

[0265] Optimal conditions for protein production will vary with the choice of the host cell and the protein to be expressed, and such conditions can be easily ascertained by those skilled in the art by routine experimentation and / or optimization.

[0266] The protein of interest can be purified or isolated after expression. The protein of interest can be isolated or purified in a variety of ways known to those skilled in the art, depending on what other components are present in the sample. Standard purification methods include, but are not limited to, electrophoretic techniques, molecular techniques, immunological techniques, chromatographic techniques, such as ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the protein of interest can be purified using a standard anti-protein of interest antibody column. In relation to protein concentration, ultrafiltration and diafiltration techniques are also useful. The degree of purification required depends on the intended use of the protein of interest. In some cases, no purification of the protein is necessary.

[0267] In certain other embodiments, various screening methods can be performed to confirm that the genetically modified fungal cells of the present disclosure produce high levels of the protein of interest. The expression vector may encode a polypeptide fusion to the target protein that serves as a detectable label, or the target protein itself may serve as a selectable or screenable marker. The labeled protein may be detected by Western blotting, dot blotting (methods available at the Cold Spring Harbor Protocols website), ELISA, or, if the label is GFP, whole cell fluorescence and / or FACS. For example, a 6-histidine tag is included as a fusion to the target protein, and this tag is detected by Western blotting. If the target protein is expressed at a sufficiently high level, SDS-PAGE combined with Coomassie / silver staining can be performed to detect increased expression in the mutant host cells over the parental (control) cells, in which case no label is required. Additionally, other methods may be used to confirm improved levels of the protein of interest, such as detection of increased protein amount per cell or per milliliter of fermentation medium using Coomassie Blue or BCA reagent-based protein separation or standard HPLC methods of total protein measurement. Determining the specific productivity is another way to evaluate the productivity of a protein. The specific productivity (Qp) can be calculated by the following formula: Qp = gP / gDCW·hr (where "gP" is the grams of protein produced in the tank, "gDCW" is the grams of dry cell weight (DCW) in the tank, and "hr" is the fermentation time (hours) from the time of inoculation, including production time as well as growth time.) Finally, if the protein of interest has enzymatic activity, its expression level can be calculated from the enzyme assay.

[0268] VI. Fermentation Certain embodiments relate to compositions and methods for producing a protein of interest, including growing, culturing or fermenting the modified (mutated) filamentous fungal cells of the present disclosure. Generally, fermentation methods known in the art are used to ferment the fungal cells. In some embodiments, the fungal cells are grown under batch, fed-batch or continuous fermentation conditions. A classical batch fermentation is a closed system in which the composition of the medium is set at the beginning of the fermentation and is not altered during the fermentation. At the beginning of the fermentation, the medium is inoculated with the desired organism. In this method, fermentation is carried out without adding any components to the system. Typically, a batch fermentation is considered to be "batch" with respect to the addition of nutrients, and factors such as pH and oxygen concentration are controlled. The broth and culture composition of a batch system are constantly changed until the fermentation is stopped. Within a batch culture, cells progress through a static lag phase to a high growth log phase and eventually to a stationary phase where the growth rate is reduced or stopped. If untreated, the cells progress to apoptosis and eventually die. Generally, in the batch phase, the majority of the production of the product occurs during the log phase.

[0269] A suitable variation on the standard batch system is the "fed-batch fermentation" system. In this variation of the typical batch system, substrate is added gradually as the fermentation progresses after the exponential phase is over. Fed-batch systems are often used to avoid catabolic repression. The continuous supply of substrate allows the process to keep its concentration below a critical level that may result in inhibition of cell metabolism and protein production. Batch and fed-batch fermentation are common and well known in the art.

[0270] Continuous fermentation is a system in which a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is simultaneously removed for processing. Continuous fermentation generally maintains the culture at a constant (high) density, with cells kept primarily in log phase growth. In other systems, many factors affecting growth can be continuously varied while the cell concentration, measured by the turbidity of the medium, is kept constant. Continuous systems attempt to maintain steady state growth conditions. Thus, cell losses due to medium removal must be balanced against the cell growth rate during fermentation. Methods for regulating nutrients and growth factors in continuous fermentation processes, as well as techniques for maximizing the rate of product formation, are well known in the art of industrial microbiology.

[0271] Certain embodiments of the present disclosure relate to fermentation procedures for culturing fungi. Fermentation procedures for the production of cellulase enzymes are known in the art. For example, cellulase enzymes can be produced by solid-state or submerged culture, such as batch, fed-batch and continuous flow processes. Cultivation is generally carried out in a growth medium that includes an aqueous inorganic salts medium, organic growth factors, carbon and energy source materials, molecular oxygen, and, of course, a starting inoculum of the filamentous fungal host used.

[0272] To ensure proper microbial growth, maximize the uptake of carbon and energy sources by the cells in the microbial conversion process, and achieve maximum cell yield at maximum cell density in the fermentation medium, suitable amounts of inorganic nutrients must be supplied in appropriate proportions in addition to the carbon and energy sources, oxygen, assimilable nitrogen, and microbial inoculum.

[0273] The composition of the aqueous mineral medium can vary widely depending in part on the microorganism and substrate used, as is known in the art. In addition to nitrogen, the mineral medium contains suitable amounts of phosphorus, magnesium, calcium, potassium, sulfur, and sodium in suitable soluble, absorbable, ionic complex forms, and several trace elements such as copper, manganese, molybdenum, zinc, iron, boron, and iodine, also in suitable soluble, absorbable forms, all of which are known in the art.

[0274] The fermentation process may be an aerobic process in which the necessary molecular oxygen is supplied by a molecular oxygen-containing gas, such as air, oxygen-enriched air, or substantially pure molecular oxygen, provided to maintain the contents of the fermenter at a suitable oxygen partial pressure effective to support vigorous growth of the microbial species.

[0275] Fermentation temperatures can vary somewhat, but for filamentous fungi such as Trichoderma reesei, temperatures are generally within the range of about 20°C to 40°C, and generally preferably within the range of about 25°C to 34°C.

[0276] Microorganisms also require an assimilable nitrogen source. The assimilable nitrogen source can be any nitrogen-containing compound or any compound that can release nitrogen in a form suitable for metabolic utilization by the microorganism. A variety of organic nitrogen source compounds, such as protein hydrolysates, can be used, but typically inexpensive nitrogen-containing compounds such as ammonia, ammonium hydroxide, urea, and various ammonium salts such as ammonium phosphate, ammonium sulfate, ammonium pyrophosphate, ammonium chloride, or various other ammonium compounds can be utilized. Ammonia gas itself is convenient for large-scale operations and can be used by bubbling the aqueous fermentation product (fermentation medium) in a suitable amount. At the same time, such ammonia can also be used to aid in pH control.

[0277] The pH range in the aqueous microbial fermentation should be in the exemplary range of about 2.0 to 10.0. For filamentous fungi, the pH is usually in the range of about 2.5 to 8.0, and for Trichoderma reesei, the pH is usually in the range of about 3.0 to 7.0. The preferred pH range for the microorganism will depend to some extent on the medium and the particular microorganism used, and therefore may be somewhat adjustable, as can be readily determined by one of skill in the art.

[0278] It is preferred to carry out the fermentation in such a way that it is possible to control the carbon-containing substrate as the limiting factor, thereby providing good conversion of the carbon-containing substrate to products and avoiding contamination of the cells with significant amounts of unconverted substrate. The latter is not a problem with water-soluble substrates, since trace amounts of residues can be easily washed away. However, it can be a problem with water-insoluble substrates, necessitating additional product processing steps, such as suitable washing steps.

[0279] As noted above, the time to reach this level is not critical and may vary depending on the particular microorganism and fermentation process being carried out, however, methods for determining the carbon source concentration in a fermentation medium and whether a desired carbon source level has been achieved are well known in the art.

[0280] Fermentation can be carried out as a batch or continuous operation, with fed-batch operation being highly preferred for ease of control, production of uniform amounts of product, and the most economical use of all equipment.

[0281] If necessary, some or all of the carbon and energy source materials and / or a portion of the assimilable nitrogen source, such as ammonia, can be added to the aqueous mineral medium before it is fed to the fermenter.

[0282] Each of the streams introduced into the reactor is preferably controlled at a predetermined rate or according to needs that can be determined by monitoring the concentrations of carbon and energy substrates, pH, dissolved oxygen, oxygen or carbon dioxide in the fermenter exhaust gas, cell density as measured by dry cell weight, light transparency, etc. The feed rates of the various materials can be varied to obtain maximum production rate and / or maximum yield.

[0283] In a batch or, preferably, fed-batch operation, all equipment, reactors, or fermentation means, tanks or vessels, piping, associated circulation or cooling devices, etc. are first sterilized, usually using steam, for example, at about 121° C. for at least about 15 minutes. The sterilized reactor is then inoculated with a culture of the selected microorganism in the presence of all necessary nutrients, including oxygen, and a carbon-containing substrate. The type of fermenter used is not critical.

[0284] Recovery and purification of the enzymes (e.g., cellulases) from the fermentation broth can also be carried out by procedures known to those of skill in the art. The fermentation broth generally contains cellular debris, e.g., cells, various suspended solids and other biomass contaminants, as well as the desired cellulase enzyme product, which are preferably removed from the fermentation broth by means known in the art.

[0285] Suitable processes for such removal include conventional solid-liquid separation techniques, such as, for example, centrifugation, filtration, dialysis, microfiltration, rotary vacuum filtration, or other known processes, to produce a cell-free filtrate. Prior to crystallization, the fermentation broth, or the cell-free filtrate, is preferably further concentrated using techniques such as ultrafiltration, evaporation, or precipitation.

[0286] Precipitation of the protein components of the supernatant or filtrate can be carried out with a salt, e.g., ammonium sulfate, or an organic solvent such as acetone, followed by purification by various chromatographic methods, e.g., ion exchange chromatography, affinity chromatography, or similar art-recognized methods.

[0287] VII. Exemplary Embodiments Non-limiting embodiments of the compositions and methods disclosed herein are as follows.

[0288] 1. A recombinant fungal cell deficient in the production of one or more native regulatory proteins that contain at least 80% identity to a Trichoderma reesei regulatory protein listed in Table 1.

[0289] 2. A recombinant fungal cell defective in the production of one or more native regulatory proteins that contain at least 80% identity to a regulatory protein homologue listed in Table 16.

[0290] 3. A recombinant fungal cell overexpressing one or more regulatory proteins comprising at least 80% identity to a Trichoderma reesei regulatory protein listed in Table 10.

[0291] 4. A recombinant fungal cell deficient in the production of one or more regulatory proteins that overexpress one or more native regulatory proteins that contain at least 80% identity to a Trichoderma reesei regulatory protein listed in Table 1 and that contain at least 80% identity to a Trichoderma reesei regulatory protein listed in Table 10.

[0292] 5. A recombinant fungal cell deficient in the production of one or more native regulatory proteins, overexpressing one or more regulatory proteins comprising at least 80% identity to a regulatory protein homologue listed in Table 16 and comprising at least 80% identity to a Trichoderma reesei regulatory protein listed in Table 10.

[0293] 6. The recombinant fungal cell of any one of embodiments 1, 2, 4 or 5, wherein the cell is defective in the production of one or more regulatory proteins that contain at least 80% identity to a DNA binding domain (DBD) shown in Table 1.

[0294] 7. A recombinant fungal cell according to any one of embodiments 1 to 6, expressing a protein of interest.

[0295] 8. A polynucleotide (e.g., an expression cassette) comprising an upstream (5') promoter (pro) operably linked to a downstream (3') nucleic acid (reg_protein) encoding a regulatory protein comprising at least 80% sequence identity to a protein set forth in Table 10 (e.g., 5'-[pro]-[reg_protein]-3').

[0296] 9. The polynucleotide of embodiment 8, wherein the upstream promoter is a constitutive promoter or an inducible promoter.

[0297] 10. The polynucleotide of embodiment 8, further comprising a downstream (3') terminator (term) sequence operably linked to the nucleic acid encoding a regulatory protein (reg_protein).

[0298] 11. A recombinant fungal cell comprising at least one introduced polynucleotide of embodiment 8.

[0299] 12. A recombinant fungal cell comprising at least one introduced polynucleotide of embodiment 8 and expressing an endogenous protein of interest.

[0300] 13. A recombinant fungal cell comprising at least one introduced polynucleotide of embodiment 8 and expressing at least one introduced cassette encoding a heterologous protein of interest (POI).

[0301] 14. The recombinant fungus of embodiment 13, wherein the introduction cassette comprises an upstream (5') cellulase gene promoter (proCel) sequence operably linked to a downstream (3') nucleic acid (POI) encoding a heterologous POI (e.g., 5'-[proCel]-[POI]-3').

[0302] 15. A recombinant fungal cell according to any one of embodiments 11 to 14, further comprising a genetic modification that renders the recombinant cell defective in the production of one or more native regulatory proteins comprising at least 80% identity to a Trichoderma reesei regulatory protein listed in Table 1.

[0303] 16. A recombinant fungal cell according to any one of embodiments 11 to 14, further comprising a genetic modification that renders the recombinant cell defective in the production of one or more native regulatory proteins that contain at least 80% identity to a regulatory protein homologue listed in Table 16.

[0304] 17. The recombinant fungal cell of embodiment 12, wherein the endogenous POI is a cellulase.

[0305] 18. The recombinant fungal cell of embodiment 17, wherein the cellulase is selected from the group consisting of cellobiohydrolases, xylanases, endoglucanases and β-glucosidases.

[0306] 19. The recombinant fungal cell of embodiment 13, wherein the heterologous POI is selected from the group consisting of enzymes, peptides, antibodies (and functional antibody fragments thereof), receptor proteins, animal feed proteins, human food proteins, protein biopharmaceuticals, therapeutic proteins, immunogenic proteins, and the like.

[0307] 20. A method for enhancing production of cellulase, comprising obtaining a parent fungal cell that expresses cellulase, genetically modifying the parent cell to obtain a recombinant fungal cell that is deficient in the production of one or more native regulatory proteins that have at least 80% identity to a regulatory protein listed in Table 1, and culturing the recombinant cell, wherein the recombinant cell produces an increased amount of cellulase relative to the parent cell cultured under the same conditions.

[0308] 21. The method of embodiment 20, wherein the recombinant cell further comprises one or more introduced polynucleotides encoding one or more regulatory proteins comprising at least 80% identity to a regulatory protein shown in Table 10.

[0309] 22. A method for enhancing production of cellulase, comprising obtaining a parent fungal cell that expresses cellulase, genetically modifying the parent cell to obtain a recombinant fungal cell that overexpresses one or more regulatory proteins that have at least 80% identity to a regulatory protein listed in Table 10, and culturing the recombinant cell, wherein the recombinant cell produces an increased amount of cellulase relative to the parent cell cultured under the same conditions.

[0310] 23. The method of embodiment 22, wherein the recombinant cell further comprises a genetic modification that renders the cell defective in the production of one or more native regulatory proteins comprising at least 80% identity to a regulatory protein of Table 1.

[0311] 24. The method of any one of embodiments 20 to 23, wherein the cellulase is selected from the group consisting of cellobiohydrolases, hemicellulases, endoglucanases and β-glucosidases.

[0312] 25. A method for enhancing production of a protein of interest (POI), comprising: introducing at least one expression cassette encoding the POI into a parent fungal cell, genetically modifying the parent cell to obtain a recombinant fungal cell defective in the production of one or more native regulatory proteins comprising at least 80% identity to a regulatory protein listed in Table 1, and culturing the recombinant cell, wherein the recombinant cell produces an increased amount of the POI relative to the parent cell cultured under the same conditions.

[0313] 26. The method of embodiment 25, wherein the cassette encoding the POI comprises an upstream (5') cellulase gene promoter operably linked to a downstream (3') nucleic acid encoding the POI.

[0314] 27. The method of embodiment 25, wherein the cassette encoding the POI is integrated into the genome of the fungal cell.

[0315] 28. The method according to embodiment 25, wherein the POI is selected from the group consisting of enzymes, peptides, antibodies (and functional antibody fragments thereof), receptor proteins, animal feed proteins, human food proteins, protein biopharmaceuticals, therapeutic proteins, immunogenic proteins, etc. EXAMPLES

[0316] The following examples show embodiments of the present disclosure, but it should be understood that they are given by way of illustration only. From the above discussion and these examples, those skilled in the art can make various changes and modifications of the present disclosure to suit various uses and conditions. Such modifications are also intended to fall within the scope of the invention as described in the claims. Standard recombinant DNA and molecular cloning techniques used herein are known in the art (Ausubel et al., 1987; Sambrook et al., 1989).

[0317] Example 1 Construction and screening of regulatory protein deletion libraries in fungal cells Overview

[0318] As generally described above in the detailed description, regulatory proteins are key regulators of cellular gene expression, and such regulatory proteins typically regulate gene expression by binding to specific (target) sites in the promoter region of the (regulated) gene. For example, binding of a regulatory protein to its target promoter site can upregulate or downregulate the transcription of genes involved in various cellular functions, processes, etc.

[0319] In this example, applicants identified over 400 regulatory proteins predicted via bioinformatics tools using Trichoderma reesei QM6a strain from the Joint Genome Institute (JGI) database (Nordberg et al., 2014). More specifically, in the examples and data presented below (see Tables 1-15), a wild-type T. reesei strain (QM6a; ATCC® 13631) was used throughout the study for molecular biological manipulations. Furthermore, to improve the efficiency of gene deletion, a ku80 disruption (Δku80) mutant impaired in the non-homologous end joining (NHEJ) mechanism was constructed by replacing the ku80 gene with a pyr4 marker (see, for example, WO 2016 / 100272, which describes the construction of such a Δku80 fungal mutant impaired in NHEJ). Thus, in one particular aspect, a library of regulatory protein deletion constructs was generated by a fusion PCR approach between gene-specific upstream (5') and downstream (3') flanking regions of approximately 2 kb length separated by a hygromycin selection marker (hphB) used for fungal transformation and selection of gene knockouts. Transformed colonies were selected on agar plates containing 2% malt extract, 0.2% peptone, 2% glucose, 1 M sorbitol, 5 mM Tris (pH 5.0) supplemented with 50 μg / ml hygromycin, followed by colony PCR analysis for correct integration of the disruption cassette at the specific locus. A total of 343 regulatory protein deletion (mutation) strains were obtained and screened for improved properties as described in the following examples.

[0320] B. Inoculum Preparation

[0321] 10 μL of the spore suspension was plated onto 24-well microtiter plates (MTPs) containing 2% malt extract agar medium (Oxoid) and incubated in the presence of light at 30° C. When sporulation was observed, the spores were harvested and incubated at the same OD 600Normalized to nm values. 50 μL of normalized spore solution was used to inoculate production plates.

[0322] C. Protein Production and Sample Preparation

[0323] T. reesei liquid cultures were grown in 24-well polystyrene plates (Corning® Costart® CLS3527) containing media containing a glucose / sophorose mixture, or plates configured to release lactose or glucose from a solid porous matrix. More specifically, each well contained 1.2 mL of production medium (9 g / L cassamino acids, 10 g / L (NH4)2SO4, 4.5 g / L KH2PO4, 1 g / L MgSO4·7H2O, 1 g / L CaCl2·2H2O, 33 g / L PIPPS buffer (pH 5.5) and 0.25% T. reesei trace elements [175 g / L C6H8O7, 200 g / L FeSO4·7H2O, 16 g / L ZnSO4·7H2O, 3.2 g / L CuSO4·5H2O, 1.4 g / L MnSO4·H2O and 0.8 g / L H3BO3]). For polystyrene plates, a glucose / sophorose mixture with a final concentration of 2% (w / w) was used as the carbon source. For glucose and lactose release plates, 1.6% (w / w) glucose was added to the production medium. Plates were incubated at 28° C. or 34° C., 80% humidity and 200 rpm (50 mM throw).

[0324] Sampling was performed after 72 and 120 hours of incubation. 200 μL of culture was harvested and filtered through 0.2 μM Corning FILTREX™ CLS3505. The resulting supernatant was used for total protein and enzyme activity measurements.

[0325] D. Protein Determination by Bradford and HPLC

[0326] Total protein concentrations in culture supernatants were determined by Bio-Rad Bradford assay using bovine serum albumin (BSA) as standard. Cellobiohydrolase 1 (CBH1) levels were measured by HPLC using an Agilent 1200 HPLC equipped with an Acquity UPLC BEH200 SEC 1.7 μm (4.6 × 150 mm) column (Waters #186005225). 25 μL of sample was mixed with 75 μL of demineralized water. 10 μL of 4-fold diluted sample was injected onto the column. To elute the sample, 25 mM NaH2PO4 (pH 6.7) and 100 mM NaCl were run isocratically for 5 min. To calculate the performance index (PI), the ratio of (average) total protein produced by the deletion mutants of the QM6a(Δku80) strain to the (average) total protein produced by the wild-type QM6A(Δku80) strain under the same conditions was compared.

[0327] E. Phosphoric acid swollen cellulose (PASC) hydrolysis assay

[0328] Phosphoric acid swollen cellulose (PASC) was prepared from Avicel according to the published method of Wood (1971) and described in WO 2014 / 093275. The material was diluted with buffer and water to obtain a 0.5% (w / v) mixture, with a final concentration of 50 mM sodium acetate (pH 5.0). CBH1 activity was determined by adding 5 μL, 10 μL, 20 μL and 40 μL of supernatant (see C) to 140 μL of reaction mixture (0.36% PASO; 29.4 mM NaOAc (pH 5.0); 143 mM NaCl) in a 96-well microtiter plate (Costar Flat Bottom PS 3641). The microtiter plate was sealed and incubated at 50° C. for 2 h with continuous shaking at 900 rpm, followed by cooling on ice for 5 min. The hydrolysis reaction was stopped by adding 100 μL of quench buffer (100 mM glycine buffer; pH 10). The hydrolysis reaction products were analyzed by the p-hydroxybenzoic acid hydrazide (PAHBAH) assay according to Lever (1972) with the following modifications.

[0329] PAHBAH Assay: An aliquot of 150 μL of PAHBAH reducing sugar reagent (for 100 mL of reagent: 1.5 g p-hydroxybenzoic acid hydrazide (Sigma #H9882), 5 g sodium potassium tartrate tetrahydrate dissolved in 2% NaOH) was added to all wells of an empty microtiter plate. 10 μL of hydrolysis reaction supernatant was added to the PAHBAH reaction plate. All plates were sealed and incubated at 69° C. under continuous shaking at 900 rpm. After 1 hour, plates were placed on ice for 5 min and centrifuged at 720×g for 5 min at room temperature. The absorbance of the plates (endpoint) was measured at 410 nm in a spectrophotometer. Cellobiose standards were included as controls and appropriate blank samples. To calculate the performance index (PI), the (average) total sugars produced by the wild-type QM6a(Δku80) strain was divided by the (average) total sugars produced by the regulatory protein deletion mutants of the QM6a(Δku80) strain.

[0330] Example 2 Improved protein production at 28°C A subset of 166 regulatory protein deletion mutants were screened for improved protein production under various conditions. For example, Table 1 below shows the T. reesei gene (DNA) sequences (SEQ ID NO: 1), predicted protein sequences (SEQ ID NO: 1), and predicted DNA binding domain (DBD) sequences (SEQ ID NO: 1) for certain T. reesei regulatory protein deletion mutants described herein. [Table 1]

[0331] More specifically, protein productivity was measured by total protein determination and enzyme activity assays (Example 1), and the regulatory proteins whose deletion led to an increase in total protein production at 28° C. are listed in Tables 2-4 below.

[0332] For example, regulatory proteins whose deletions led to increased protein production at 28°C in lactose release plates after 120 h of incubation are listed in Table 2, and the numbers represent the performance indices (PIs) calculated for the PASC enzyme assay, HPLC measurements of CBH1, and total protein measured by Bradford, relative to the control (wild-type) strain QM6aΔku80. [Table 2]

[0333] As shown in Table 2, mutant cells containing a deletion of the regulatory protein Trire2_76872 (SEQ ID NO: 44) contain an enhanced protein productivity phenotype (i.e., relative to the parent cells) when fermented at 28°C under lactose-releasing (inducing) conditions; mutant cells defective in the production of the regulatory protein Trire2_76872 (SEQ ID NO: 44) produce increased amounts of total protein and increased amounts of CBH1, resulting in higher saccharification activity (as exemplified by the PASC assay relative to the parent strain).

[0334] Similarly, regulatory proteins whose deletion led to increased protein production at 28°C in glucose release plates after 120 h of incubation are listed in Table 3, with numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1, or Bradford, relative to the control (wild-type) strain QM6aΔku80. [Table 3]

[0335] For example, as shown in Table 3, mutant cells comprising deletions of regulatory proteins Trire2_76872 (SEQ ID NO: 44), Trire2_120428 (SEQ ID NO: 71), Trire2_76705 (SEQ ID NO: 41), Trire2_78162 (SEQ ID NO: 50) or Trire2_105239 (SEQ ID NO: 56) comprise an enhanced protein productivity phenotype (relative to the parent cells) when fermented under glucose-releasing conditions at 28° C. More specifically, such mutant cells deficient in the production of the above-mentioned regulatory proteins (Table 3) produced increased amounts of total protein and / or increased amounts of CBH1 (relative to the parent cells) under such glucose-releasing conditions.

[0336] Additionally, listed below in Table 4 are regulatory proteins whose deletion resulted in increased protein production at 28°C in polystyrene plates containing 2% (w / w) glucose / sophorose as carbon source after 120 hours of incubation, the numbers represent the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1, or Bradford, relative to the control (wild type) strain QM6aΔku80. [Table 4]

[0337] As shown in Table 4 above, the regulatory proteins Trire2_69695 (SEQ ID NO: 32), Trire2_76705 (SEQ ID NO: 41), Trire2_78162 (SEQ ID NO: 50), Trire2_105849 (SEQ ID NO: 59), Trire2_71823 (SEQ ID NO: 35), Trire2_60931 (SEQ ID NO: 20), Trire2_48438 (SEQ ID NO: 8), Trire2_108013 (SEQ ID NO: 62), Trire2_68097 (SEQ ID NO: 26), Trire2_4933 (SEQ ID NO: 2), Trire2_72 Mutant cells comprising deletions of 993 (SEQ ID NO:38), Trire2_119986 (SEQ ID NO:68), Trire2_55105 (SEQ ID NO:14), Trire2_68425 (SEQ ID NO:29), Trire2_103122 (SEQ ID NO:53), Trire2_5675 (SEQ ID NO:5), Trire2_121757 (SEQ ID NO:77) or Trire2_77291 (SEQ ID NO:47) comprise an enhanced protein productivity phenotype (relative to the parent cells) when fermented at 28° C. with 2% (w / w) glucose / sophorose as the carbon source. For example, mutant cells deficient in the production of the above-mentioned regulatory proteins (Table 4) produce increased amounts of total protein and / or increased amounts of CBH1 (relative to the parent cells) under such glucose / sophorose (inducing) conditions.

[0338] Example 3 Improved protein production at 34°C In this example, Applicant screened 166 regulatory protein deletion library mutants (Example 2) to determine whether any of the regulatory protein deletions further resulted in improved protein production at higher incubation temperatures of 34° C. (see, e.g., Tables 5 and 6). Protein productivity was measured by total protein determination and enzyme activity assays (Example 1). For example, regulatory proteins whose deletions resulted in increased protein production at 34° C. in lactose release plates after 120 hours of incubation are listed in Table 5, with the numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1 or Bradford, relative to the control (wild type) strain QM6aΔku80. [Table 5]

[0339] As shown in Table 5 above, mutant cells comprising deletions of the regulatory proteins Trire2_76872 (SEQ ID NO: 44), Trire2_67209 (SEQ ID NO: 23) or Trire2_122783 (SEQ ID NO: 80) comprise an enhanced protein productivity phenotype (relative to the parent cells) when fermented under lactose releasing conditions at 34° C. For example, mutant cells deficient in the production of the above mentioned regulatory proteins (Table 5) produce increased amounts of total protein and / or increased amounts of CBH1 (relative to the parent cells) under such lactose (inducing) conditions.

[0340] Similarly, regulatory proteins whose deletion led to increased protein production at 34°C in glucose release plates after 120 h of incubation are listed in Table 6, with the numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1 or Bradford relative to the control (wild-type) strain QM6aΔku80. [Table 6]

[0341] Thus, as shown in Table 6 above, mutant cells comprising deletions of the regulatory proteins Trire2_76705 (SEQ ID NO: 41), Trire2_120597 (SEQ ID NO: 74), Trire2_49232 (SEQ ID NO: 11), Trire2_108775 (SEQ ID NO: 65) or Trire2_60565 (SEQ ID NO: 17) comprise an enhanced protein productivity phenotype (relative to the parent cells) when fermented under glucose releasing conditions at 34° C. For example, mutant cells deficient in the production of the above-mentioned regulatory proteins (Table 6) produce increased amounts of total protein and / or increased amounts of CBH1 at 34° C. in the absence of an inducing substrate (relative to the parent cells).

[0342] Example 4 Improved protein production rate In this example, regulatory proteins whose deletions resulted in higher protein production rates were determined by comparing protein production at early time points of 72 hours, followed by a final protein production measurement at 120 hours. More specifically, only regulatory proteins whose deletions resulted in higher production at 72 hours and equivalent or improved protein production at 120 hours compared to the control (wild type) strain QM6aΔku80 were selected, as shown in Tables 7-9 below.

[0343] For example, regulatory proteins whose deletions led to increased protein production rates in lactose release plates after 72 hours of incubation at 28°C or 34°C are listed below in Table 7, where the numbers represent the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1 or Bradford relative to the control (wild type) strain QM6aΔku80. [Table 7]

[0344] As shown in Table 7 above, mutant cells comprising a deletion of the regulatory protein Trire2_76872 (SEQ ID NO: 44) comprise an enhanced protein production rate (relative to the parent cells) after 72 hours of culture at 28° C. on lactose release plates. Additionally, as shown in Table 7, mutant cells comprising a deletion of the regulatory protein Trire2_76872 (SEQ ID NO: 44) comprise an enhanced protein production rate (relative to the parent cells) after 72 hours of culture at 34° C. on lactose release plates. Thus, as illustrated above, mutant cells deficient in the production of the above-mentioned regulatory proteins (Table 7) exhibit increased protein production rates (relative to the parent cells).

[0345] Similarly, regulatory proteins whose deletions led to increased protein production rates in glucose release plates after 72 hours of incubation at 28°C or 34°C are listed below in Table 8, where the numbers represent the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1, or Bradford, relative to the control (wild type) strain QM6aΔku80. [Table 8]

[0346] As shown in Table 8 above, mutant cells comprising a deletion of the regulatory protein Trire2_76872 (SEQ ID NO: 44) comprise an enhanced protein production rate (i.e., relative to the parent cells) after 72 hours of culture at 28° C. on glucose-releasing plates. Similarly, as shown above in Table 8, mutant cells comprising a deletion of the regulatory proteins Trire2_76872 (SEQ ID NO: 44) or Trire2_78162 (SEQ ID NO: 50) comprise an enhanced protein production rate after 72 hours of culture at 34° C. on glucose-releasing plates. Thus, as illustrated above, mutant cells deficient in the production of the above-mentioned regulatory proteins (Table 8) exhibit increased protein production rates (relative to the parent cells).

[0347] Additionally, regulatory proteins whose deletion resulted in an increase in protein production rate in polystyrene plates containing 2% glucose / sophorose as carbon source after 72 hours of incubation at 28°C are listed below in Table 9, where the numbers represent the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1, or Bradford, relative to the control (wild type) strain QM6aΔku80. [Table 9]

[0348] As shown in Table 9 above, mutant cells containing deletions of the regulatory proteins Trire2_78162 (SEQ ID NO: 50) or Trire2_105849 (SEQ ID NO: 59) contain enhanced protein production rates after 72 hours of culture at 28° C. in medium containing 2% (w / w) glucose / sophorose as the carbon source. Thus, as exemplified above, mutant cells defective in the production of the above-mentioned regulatory proteins (Table 9) show increased protein production rates (relative to the parent cells).

[0349] Example 5 Decreased protein production at 28°C A subset of 166 regulatory protein deletion mutants were screened for improved protein production under various conditions. Protein productivity was measured by total protein determination and enzyme activity assay (Example 1). For example, Table 10 below shows the predicted protein sequences (SEQ ID NOs) of T. reesei regulatory protein deletion mutants whose regulatory protein deletions resulted in reduced total protein production. [Table 10-1] [Table 10-2]

[0350] For example, regulatory proteins whose deletions resulted in reduced protein production at 28°C in lactose release plates after 120 hours of incubation are listed below in Table 11, where the numbers represent the performance indices (PI) calculated for the PASC enzyme assay, HPLC measurements of CBH1, and total protein measured by Bradford, relative to the control (wild type) strain QM6aΔku80. [Table 11]

[0351] As shown in Table 11, the regulatory proteins Trire2_3605 (SEQ ID NO: 84), Trire2_4748 (SEQ ID NO: 85), Trire2_44781 (SEQ ID NO: 93), Trire2_48773 (SEQ ID NO: 95), Trire2_53484 (SEQ ID NO: 100), Trire2_58130 (SEQ ID NO: 103), Trire2_59609 (SEQ ID NO: 105), Trire2_65070 (SEQ ID NO: 108), Trire2_65895 (SEQ ID NO: 109), Trire2_71080 (SEQ ID NO: 113), Trire2_71689 (SEQ ID NO: 114), Trire2_72060 (SEQ ID NO: 115), Trire2_72080 (SEQ ID NO: 116), Trire2_72090 (SEQ ID NO: 117), Trire2_72091 (SEQ ID NO: 118), Trire2_72092 (SEQ ID NO: 119), Trire2_72093 (SEQ ID NO: 120), Trire2_72094 (SEQ ID NO: 121), Trire2_72095 (SEQ ID NO: 122), Trire2_72096 (SEQ ID NO: 123), Trire2_72097 (SEQ ID NO: 124), Trire2_72098 (SEQ ID NO: 125), Trire2_72099 (SEQ ID NO: 126), Trire2_72091 (SEQ ID NO: 127), Trire2_72095 (SEQ ID NO: 128), Trire2_72 Mutant cells containing deletions of ire2_72076 (SEQ ID NO:115), Trire2_73559 (SEQ ID NO:117), Trire2_73689 (SEQ ID NO:118), Trire2_76039 (SEQ ID NO:119), Trire2_119826 (SEQ ID NO:131), Trire2_121164 (SEQ ID NO:132), Trire2_121602 (SEQ ID NO:134) or Trire2_122457 (SEQ ID NO:135) contain a reduced (reduced) protein productivity phenotype (i.e., relative to the parent cells) when fermented under lactose (inducing) conditions at 28° C. For example, mutant cells defective in the production of the above-mentioned regulatory proteins (Table 11) result in reduced amounts of total protein, reduced amounts of CBH1, and lower saccharification activity (as exemplified by the PASC assay compared to the parent strain).

[0352] Similarly, regulatory proteins whose deletion led to a decrease in protein production at 28°C in glucose release plates after 120 h of incubation are listed in Table 12, with the numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1 or Bradford relative to the control (wild type) strain QM6aΔku80. [Table 12]

[0353] For example, as shown in Table 12, the regulatory proteins Trire2_1941 (SEQ ID NO: 82), Trire2_2148 (SEQ ID NO: 83), Trire2_5664 (SEQ ID NO: 86), Trire2_5927 (SEQ ID NO: 87), Trire2_21997 (SEQ ID NO: 88), Trire2_22785 (SEQ ID NO: 90), Trire2_36703 (SEQ ID NO: 91), Trire2_48773 (SEQ ID NO: 95), Trire2_49918 (SEQ ID NO: 96), Trire2_23703 (SEQ ID NO: 97), Trire2_24703 (SEQ ID NO: 98), Trire2_25513 (SEQ ID NO: 99), Trire2_26016 (SEQ ID NO: 100), Trire2_27018 (SEQ ID NO: 101), Trire2_28015 (SEQ ID NO: 102), Trire2_29016 (SEQ ID NO: 103), Trire2_36703 (SEQ ID NO: 104), Trire2_48773 (SEQ ID NO: 105), Trire2_49918 (SEQ ID NO: 106), Trire2_29019 (SEQ ID NO: 107), Trire2_36703 (SEQ ID NO: 108), Trire2_48773 (SEQ ID NO: 109), Trire2_5927 (SEQ ID NO: 110), Trire2_21997 (SEQ ID NO: 111), Trire2_22785 (SEQ ID NO: 112), Trire2_36703 (SEQ ID NO 2_52438 (SEQ ID NO: 97), Trire2_52924 (SEQ ID NO: 98), Trire2_53106 (SEQ ID NO: 99), Trire2_55274 (SEQ ID NO: 101), Trire2_56214 (SEQ ID NO: 102), Trire2_59353 (SEQ ID NO: 104), Trire2_59609 (SEQ ID NO: 105), Trire2_60558 (SEQ ID NO: 106), Trire2_61476 (SEQ ID NO: 107), Trire2_65895 (SEQ ID NO: 109), Tr ire2_70414 (SEQ ID NO: 111), Trire2_70991 (SEQ ID NO: 112), Trire2_71689 (SEQ ID NO: 114), Trire2_73417 (SEQ ID NO: 116), Trire2_76590 (SEQ ID NO: 120), Trire2_77878 (SEQ ID NO: 121), Trire2_105784 (SEQ ID NO: 122), Trire2_105880 (SEQ ID NO: 123), Trire2_105917 (SEQ ID NO: 124), Trire2_105980 (SEQ ID NO: Mutant cells comprising deletions of Trire2_105989 (SEQ ID NO: 126), Trire2_106009 (SEQ ID NO: 127), Trire2_106720 (SEQ ID NO: 128), Trire2_109277 (SEQ ID NO: 129), Trire2_110901 (SEQ ID NO: 130) or Trire2_121310 (SEQ ID NO: 133) comprise a reduced (reduced) protein productivity phenotype (relative to the parent cells) when fermented at 28° C. under glucose-releasing conditions. For example, mutant cells defective in the production of the above-mentioned regulatory proteins (Table 12) produce reduced amounts of total protein or reduced amounts of CBH1 (relative to the parent cells) under such glucose-releasing conditions.

[0354] Additionally, listed below in Table 13 are the deleted regulatory proteins that resulted in reduced protein production at 28°C in polystyrene plates containing 2% (w / w) glucose / sophorose as the carbon source after 120 hours of incubation, with the numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1, or Bradford, relative to the control (wild type) strain QM6aΔku80. [Table 13]

[0355] As shown in Table 13, mutant cells containing deletions of regulatory proteins Trire2_1941 (SEQ ID NO: 82), Trire2_22785 (SEQ ID NO: 90), Trire2_44290 (SEQ ID NO: 92), Trire2_44781 (SEQ ID NO: 93), Trire2_45866 (SEQ ID NO: 94), Trire2_48773 (SEQ ID NO: 95), Trire2_72076 (SEQ ID NO: 115) or Trire2_76590 (SEQ ID NO: 120) contain a reduced protein productivity phenotype (relative to the parent cells) when fermented at 28° C. with 2% (w / w) glucose / sophorose as the carbon source. For example, mutant cells defective in the production of the above-mentioned regulatory proteins (Table 13) produce reduced amounts of total protein or reduced amounts of CBH1 (relative to the parent cells) under such glucose / sophorose conditions.

[0356] Example 6 Decreased protein production at 34°C In this example, Applicant screened 166 regulatory protein deletion library mutants (Example 2) to determine whether any of the regulatory protein deletions further resulted in reduced protein production at higher temperatures of 34° C. (see, e.g., Tables 14 and 15). Protein productivity was measured by total protein determination and enzyme activity assays (Example 1). For example, regulatory proteins whose deletions resulted in reduced protein production at 34° C. in lactose release plates after 120 hours of incubation are listed in Table 14, with the numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1 or Bradford against the control (wild type) strain QM6aΔku80. [Table 14]

[0357] Thus, as shown in Table 14 above, mutant cells comprising a deletion of regulatory proteins Trire2_4748 (SEQ ID NO: 85), Trire2_21997 (SEQ ID NO: 88), Trire2_22774 (SEQ ID NO: 89), Trire2_22785 (SEQ ID NO: 90), Trire2_36703 (SEQ ID NO: 91), Trire2_44290 (SEQ ID NO: 92), Trire2_44781 (SEQ ID NO: 93), Trire2_59609 (SEQ ID NO: 105), Trire2_68028 (SEQ ID NO: 110), Trire2_71689 (SEQ ID NO: 114), Trire2_72076 (SEQ ID NO: 115) or Trire2_77878 (SEQ ID NO: 121) comprise a reduced (reduced) protein productivity phenotype (relative to the parental cells) when fermented at 34° C. under lactose releasing conditions. For example, mutant cells defective in the production of the regulatory proteins mentioned above (Table 14) produce reduced amounts of total protein and reduced amounts of CBH1 (relative to the parental cells) under such lactose-inducing conditions.

[0358] Similarly, regulatory proteins whose deletion led to a decrease in protein production at 34°C in glucose release plates after 120 hours of incubation are listed in Table 15, with the numbers representing the performance index (PI) calculated for total protein measured by PASC enzyme assay, HPLC measurement of CBH1 or Bradford relative to the control (wild type) strain QM6aΔku80. [Table 15]

[0359] Thus, as shown in Table 15 above, mutant cells comprising deletions of the regulatory proteins Trire2_22774 (SEQ ID NO: 89), Trire2_22785 (SEQ ID NO: 90), Trire2_44290 (SEQ ID NO: 92), Trire2_44781 (SEQ ID NO: 93), Trire2_48773 (SEQ ID NO: 95), Trire2_72076 (SEQ ID NO: 115), Trire2_106009 (SEQ ID NO: 127) or Trire2_123713 (SEQ ID NO: 136) comprise a reduced protein productivity phenotype (relative to the parent cells) when fermented under glucose-releasing conditions at 34° C. For example, mutant cells deficient in the production of the above-mentioned regulatory proteins (Table 15) produce reduced amounts of total protein and reduced amounts of CBH1 under such glucose-releasing conditions (relative to the parent cells).

[0360] Example 7 Fungal regulatory protein orthologues In this example, Applicants performed a homology-based search of 36 regulators for the fungal species Aspergillus niger ATCC 1015 v4.0, Myceliophthora thermophila (Sporotrichum thermophile) v2.0, and Aspergillus oryzae RIB40. As shown below, Table 16 lists the orthologs identified for these selected fungal species groups. [Table 16-1] [Table 16-2] [Table 16-3]

[0361] References European Patent No. 0215594 International Publication No. 2021 / 102238 Brochure International Publication No. 2008 / 097619 Brochure International Publication No. 2005 / 056772 Brochure International Publication No. 2008 / 080017 Brochure International Publication No. 2011 / 151512 Brochure International Publication No. 2011 / 151513 Brochure International Publication No. 2011 / 151515 Brochure International Publication No. 2011 / 153449 Brochure International Publication No. 2013 / 102674 Brochure International Publication No. 2014 / 093275 Brochure International Publication No. 2016 / 100272 Brochure U.S. Patent No. 6,022,725 U.S. Patent No. 6,255,115 U.S. Patent No. 6,268,328 Aro et al., “Transcriptional regulation of plant cell wall degradation by filamentous fungi” FEMS Microbiology Reviews 29:719-739.2005. Ausubel et al.,「Current Protocols in Molecular Biology,published by Greene Publishing Assoc. and Wiley-Interscience(1987,1989 and 2003). Boel et al.,「Two different types of intervening sequences in the glucoamylase gene from Aspergillus niger」,EMBO J. 3:1581-1585,1984. Campbell et al.,Curr.Genet.,16:53-56,1989. Cao et al.,「Penicillopepsin-JT2,a recombinant enzyme from Penicillium janthinellum and the contribution of a hydrogen bond in subsite S3 to kcat」,Protein Science(9):991-1001,2000. Devereux et al.,Nucleic Acids Res.12:387-395,1984. Druzhinina and Kubicek,「Genetic engineering of T. reesei cellulases and their production」,Microb.Biotechnol.10,1485-1499,2017. Fitz et al.「The Promoter Toolbox for Recombinant Gene Expression in Trichoderma reesei」,Frontiers in Bioengineering and Biotechnology,Volume 6,Article 135,2018. Harkki et al.,「A Novel Fungal Expression System:Secretion of Active Calf Chymosin from the Filamentous Fungus Trichoderma reesei」,BioTechnol.,7:596-603,1989. Harkki et al.,「Genetic engineering of Trichoderma to produce strains with novel cellulase profiles」,Enzyme Microb.Technol.,13:227-233,1991. Ilmen et al.,「Regulation of cellulase gene expression in the filamentous fungus Trichoderma reesei」,Applied and Environmental Microbiology,63(4)-1298-1306,1997. Kriegler,Gene Transfer and Expression:A Laboratory Manual,1990. Kubicek et al.,「Metabolic engineering strategies for the improvement of cellulase production by Hypocrea jecorina」,Biotechnol.Biofuels 2:19,2009. Latchman,「Transcription factors:an overview」,Int. J. Exp.Path.,74,417-422,1993. Lever,「A new reaction for colorimetric determination of carbohydrates」,Anal.Biochem.,47:273-279,1972. Li,Wan-Chen et al.「Trichoderma reesei complete genome sequence,repeat-induced point mutation,and partitioning of CAZyme gene clusters.」Biotechnology for biofuels Vol. 10(170),2017. Mullaney et al.,「Primary structure of the trpC gene from Aspergillus nidulans」,Molecular and General Genetics 199:37-45,1985. Needleman and Wunsch,「A general method applicable to the search for similarities in the amino acid sequence of two proteins」,J. Mol.Biol.48:443-453,1970. Nordberg et al.,「The genome portal of the Department of Energy Joint Genome Institute:2014 updates」,Nucleic Acids Res.,42(1):D26-31,2014. Nunberg et al.,「Molecular cloning and characterization of the glucoamylase gene of Aspergillus awamori」,Mol.Cell Biol.4:2306,1984. Pearson and Lipman,Proc.Natl.Acad.Sci.USA 85:2444,1988. Portnoy et al.,「Differential Regulation of the Cellulase Transcription Factors XYR1,ACE2,and ACE1 in Trichoderma reesei Strains Producing High and Low Levels of Cellulase」,Eukaryotic Cell,10(2):262-271,2011. Rice et al.,「EMBOSS:The European Molecular Biology Open Software Suite」,Trends in Genetics 16:276-277,2000. Sambrook et al.,Molecular Cloning,A Laboratory Manual,2 nd Edition,Cold Spring Harbor Laboratory Press,Cold Spring,New York,1989. Sambrook et al.,Molecular Cloning,A Laboratory Manual,4 th Edition,Cold Spring Harbor Laboratory Press,Cold Spring,New York,2012. Sheir-Neiss and Montenecourt,「Characterization of the secreted cellulases of Trichoderma reesei wild type and mutants during controlled fermentations」,Applied Microbiology and Biotechnology,20(1):46-53,1984. Smith and Waterman,Adv.Appl.Math.2:482,1981. Stricker et al.,「Regulation of transcription of cellulases- and hemicellulases-encoding genes in Aspergillus niger and Hypocrea jecorina(Trichoderma reesei),Appl.Microbiol.Biotechnol.(Review),78(2):211-220,2008. Wang et al.,「Fermentation & Enzyme Technology」,John Wiley & Sons,1979. Wood,「The cellulase of Fusarium solani.Purification and specificity of the β-(1→4)-glucanase and the β-d-glucosidase components」,Biochem.J.,121:353-362,1971. Wu et al.,「The regulatory and transcriptional landscape associated with carbon utilization in a filamentous fungus」,PNAS,117(11):6003-6013,2020. Yelton et al.,「Transformation of Aspergillus nidulans by using a trpC plasmid」,PNAS USA 81:1470-1474,1984.

Claims

1. A recombinant fungal cell that is deficient in the production of one or more regulatory proteins that contain at least 80% identity to a regulatory protein listed in Table 1.

2. A recombinant fungal cell overexpressing one or more regulatory proteins comprising at least 80% identity to a regulatory protein listed in Table 10.

3. A recombinant fungal cell deficient in the production of one or more regulatory proteins that overexpress one or more regulatory proteins that contain at least 80% identity to a regulatory protein listed in Table 1 and that contain at least 80% identity to a regulatory protein listed in Table 10.

4. 4. The recombinant fungal cell of claim 1 or claim 3, wherein the cell is deficient in the production of one or more regulatory proteins that contain at least 80% identity to a DNA binding domain (DBD) listed in Table 1.

5. A recombinant fungal cell according to any one of claims 1 to 4, which expresses a protein of interest.

6. A polynucleotide comprising an upstream (5') promoter operably linked to a downstream (3') nucleic acid encoding a regulatory protein that contains at least 80% sequence identity to a protein shown in Table 10.

7. A recombinant fungal cell comprising at least one introduced polynucleotide according to claim 6.

8. A recombinant fungal cell comprising at least one introduced polynucleotide according to claim 6 and expressing an endogenous protein of interest (POI).

9. A recombinant fungal cell comprising at least one transfer polynucleotide according to claim 6 and expressing at least one transfer cassette encoding a heterologous protein of interest (POI).

10. 10. The recombinant fungal cell of claim 9, wherein the transfer cassette comprises an upstream (5') cellulase gene promoter operably linked to a downstream (3') nucleic acid encoding the heterologous POI.

11. The recombinant fungal cell of any one of claims 7 to 10, further comprising a genetic modification that renders the recombinant cell defective in the production of one or more regulatory proteins that contain at least 80% identity to a regulatory protein shown in Table 1.

12. The recombinant fungal cell of claim 8 , wherein the endogenous POI is a cellulase.

13. The recombinant fungal cell of claim 9, wherein the heterologous POI is selected from the group consisting of an enzyme, a peptide, an antibody, a receptor protein, an animal feed protein, a human food protein, a protein biopharmaceutical, a therapeutic protein and an immunogenic protein.

14. 1. A method for enhancing cellulase production, comprising: (a) obtaining a parent fungal cell expressing a cellulase and genetically modifying said parent cell to obtain a recombinant fungal cell deficient in the production of one or more native regulatory proteins that contain at least 80% identity to a regulatory protein listed in Table 1; (b) culturing the recombinant cell, The method of claim 1, wherein the recombinant cells of the process produce increased amounts of cellulase relative to the parent cells cultured under the same conditions.

15. 15. The method of claim 14, wherein the recombinant cell further comprises one or more introduced polynucleotides encoding one or more regulatory proteins comprising at least 80% identity to a regulatory protein listed in Table 10.

16. 1. A method for enhancing cellulase production, comprising: (a) obtaining a parent fungal cell expressing a cellulase and genetically modifying said parent cell to obtain a recombinant fungal cell thereof that overexpresses one or more regulatory proteins comprising at least 80% identity to a regulatory protein listed in Table 10; (b) culturing the recombinant cell, The method of claim 1, wherein the recombinant cells of the process produce increased amounts of cellulase relative to the parent cells cultured under the same conditions.

17. 17. The method of claim 16, wherein the recombinant cell further comprises a genetic modification that renders the cell defective in the production of one or more native regulatory proteins that comprise at least 80% identity to a regulatory protein of Table 1.

18. The method according to any one of claims 14 to 17, wherein the cellulase is selected from the group consisting of cellobiohydrolases, hemicellulases, endoglucanases and β-glucosidases.

19. 1. A method for enhancing production of a protein of interest (POI), comprising: (a) introducing an expression cassette encoding a POI into a parent fungal cell and genetically modifying said parent cell to obtain a recombinant fungal cell defective in the production of one or more native regulatory proteins that contain at least 80% identity to a regulatory protein listed in Table 1; (b) culturing the recombinant cell, The method, wherein the recombinant cells produce increased amounts of the POI relative to the parent cells cultured under the same conditions.

20. 20. The method of claim 19, wherein the cassette encoding the POI comprises an upstream (5') cellulase gene promoter operably linked to a downstream (3') nucleic acid encoding the POI.

21. 20. The method of claim 19, wherein the POI is selected from the group consisting of an enzyme, a peptide, an antibody, a receptor protein, an animal feed protein, a human food protein, a protein biopharmaceutical, a therapeutic protein and an immunogenic protein.